Myomo (MYO) 10-K 12 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 06, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	MYO
Entity Registrant Name	MYOMO INC
Entity Central Index Key	1,369,290
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		12,392,536
Entity Public Float			$ 35,443,695

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 12,959,373	$ 797,174
Accounts receivable	297,039	114,506
Inventories, net	201,155	82,435
Prepaid expenses and other	388,275	152,337
Total Current Assets	13,845,842	1,146,452
Restricted cash	52,000	52,000
Deferred offering costs		438,237
Equipment, net	77,150	21,563
Total Assets	13,974,992	1,658,252
Current Liabilities:
Notes payable, shareholder		876,458
Notes payable, MLSC, current		1,193,984
Accounts payable and other accrued expenses	1,277,236	714,010
Accrued interest		149,580
Derivative liabilities	39,930
Deferred revenue	168,006	67,263
Total Current Liabilities	1,485,172	3,001,295
Convertible promissory notes, net of debt discount		2,204,235
Convertible promissory notes, related party		1,180,000
Accrued interest		130,937
Deferred revenue, net of current portion	44,042
Total liabilities	1,529,214	6,516,467
Redeemable and Convertible Preferred Stock:
Total Redeemable and Convertible Preferred Stock		12,672,241
Commitments and Contingencies
Stockholders' Equity (Deficiency)
Common stock par value $0.0001 per share 100,000,000 shares authorized; 11,139,667 and 1,124,888 shares issued as of December 31, 2017 and 2016, respectively, and 11,138,859 and 1,124,080 shares outstanding as of December 31, 2017 and 2016, respectively.	1,114	112
Undesignated preferred stock par value $0.0001 per share; 25,000,000 authorized at December 31, 2017. No shares issued or outstanding
Additional paid-in capital	47,423,915	5,351,204
Accumulated deficit	(34,972,787)	(22,875,308)
Treasury stock, at cost; 808 shares of common stock	(6,464)	(6,464)
Total Stockholders' Equity (Deficiency)	12,445,778	(17,530,456)
Total Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficiency)	12,445,778	(4,858,215)
Total Liabilities, Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficiency)	$ 13,974,992	1,658,252
Series B-1 Convertible Preferred Stock [Member]
Redeemable and Convertible Preferred Stock:
Total Redeemable and Convertible Preferred Stock		8,174,693
Stockholders' Equity (Deficiency)
Total Stockholders' Equity (Deficiency)		8,174,693
Series A-1 Convertible Preferred Stock [Member]
Redeemable and Convertible Preferred Stock:
Total Redeemable and Convertible Preferred Stock		4,497,548
Stockholders' Equity (Deficiency)
Total Stockholders' Equity (Deficiency)		$ 4,497,548

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,139,667	1,124,888
Common stock, shares outstanding	11,138,859	1,124,080
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	25,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Treasury shares at cost	808	808
Series B-1 Convertible Preferred Stock [Member]
Convertible preferred stock, par value		$ 0.0001
Convertible preferred stock, shares authorized		1,862,500
Convertible preferred stock, shares issued		1,662,104
Convertible preferred stock, shares outstanding		1,662,104
Convertible preferred stock, liquidation preference		$ 9,701,313
Series A-1 Convertible Preferred Stock [Member]
Convertible preferred stock, par value		$ 0.0001
Convertible preferred stock, shares authorized		1,594,958
Convertible preferred stock, shares issued		960,083
Convertible preferred stock, shares outstanding		960,083
Convertible preferred stock, liquidation preference		$ 4,740,066

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenue	$ 1,558,866	$ 1,103,277
Cost of revenue	505,280	282,164
Gross margin	1,053,586	821,113
Operating expenses:
Research and development	1,751,731	1,120,951
Selling, general and administrative	5,849,969	2,975,164
Total operating expenses	7,601,700	4,096,115
Loss from operations	(6,548,114)	(3,275,002)
Other expense (income)
Loss on early extinguishment of debt	135,244
Change in fair value of derivative liabilities	(116,795)
Debt discount on convertible notes	5,172,000
Interest and other expense, net	358,916	342,020
Total other expense (income)	5,549,365	342,020
Net loss	(12,097,479)	(3,617,022)
Deemed dividend - accreted preferred stock	(274,011)	(108,739)
Cumulative dividend to Series B-1 preferred stockholders	(287,779)	(658,293)
Net loss available to common stockholders	$ (12,659,269)	$ (4,384,054)
Weighted average number of common shares outstanding:
Basic and diluted	4,317,864	1,060,892
Net loss per share available to common stockholders:
Basic and diluted	$ (2.93)	$ (4.13)

Statements of Changes in Redeem

Statements of Changes in Redeemable and Convertible Preferred Stock and Stockholders' (Deficiency) Equity - USD ($)	Total	Series B-1 Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	IPO [Member]	IPO [Member]Common Stock [Member]	IPO [Member]Additional Paid-in Capital [Member]	Over-allotment Option [Member]	Over-allotment Option [Member]Common Stock [Member]	Over-allotment Option [Member]Additional Paid-in Capital [Member]
Beginning balance at Dec. 31, 2015	$ (13,901,662)	$ 8,162,406	$ 4,401,095	$ 100	$ 5,362,988	$ (19,258,286)	$ (6,464)
Beginning balance, shares at Dec. 31, 2015		1,662,104	960,083	999,624			808
Common stock issued for the exercise of common stock options	$ 2,873			$ 12	2,861
Common stock issued for the exercise of common stock options, shares	124,459			124,456
Accretion of preferred stock	$ (108,739)	$ 12,287	$ 96,453		(108,739)
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock, Shares				2,622,187
Stock-based compensation	94,094				94,094
Net loss	(3,617,022)					(3,617,022)
Ending balance at Dec. 31, 2016	(17,530,456)	$ 8,174,693	$ 4,497,548	$ 112	5,351,204	(22,875,308)	$ (6,464)
Ending balance, shares at Dec. 31, 2016		1,662,104	960,083	1,124,080			808
Common stock issued for the exercise of common stock options	$ 26,954			$ 8	26,946
Common stock issued for the exercise of common stock options, shares	80,085			80,085
Accretion of preferred stock	$ (274,011)	$ 31,493	$ 242,518		(274,011)
Proceeds from offering costs								$ 3,930,078	$ 67	$ 3,930,011	$ 10,407,706	$ 480	$ 10,407,226
Proceeds from offering costs, shares									665,498			4,801,250
Proceeds from private placement, net of offering costs of $2,500	2,922,885			$ 56	2,922,829
Proceeds from private placement, net of offering costs of $2,500, shares				557,216
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock	12,946,252	$ (8,206,186)	$ (4,740,066)	$ 262	12,945,990
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock, Shares		(1,662,104)	(960,083)	2,622,187
Conversion of convertible promissory notes into common stock	5,467,389			$ 106	5,467,283
Conversion of convertible promissory notes into common stock, shares				1,055,430
Fair value of warrants issued with convertible promissory notes	5,172,000				5,172,000
Warrants issued to IPO selling agent deemed to be derivative liability	(156,725)				(156,725)
Common stock issued for the exercise of warrants	$ 102,660			$ 3	102,657
Common stock issued for the exercise of warrants, shares	34,800			34,800
Restricted stock vested	$ 0	$ 0	$ 0	$ 0	0	0	$ 0
Restricted stock vested, shares				312
Shares of common stock issued for services	30,000				30,000
Shares of common stock issued for services, shares				4,000
Shares of common stock issued for repayment of promissory notes	1,217,172			$ 19	1,217,153
Shares of common stock issued for repayment of promissory notes, shares				193,509
Additional shares issued pursuant to software license agreement	1,845			$ 1	1,844
Additional shares issued pursuant to software license agreement, shares				492
Stock-based compensation	279,508				279,508
Net loss	(12,097,479)					(12,097,479)
Ending balance at Dec. 31, 2017	$ 12,445,778			$ 1,114	$ 47,423,915	$ (34,972,787)	$ (6,464)
Ending balance, shares at Dec. 31, 2017				11,138,859			808

Statements of Changes in Redee6

Statements of Changes in Redeemable and Convertible Preferred Stock and Stockholders' (Deficiency) Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2017USD ($)
Offering cost from private placement	$ 2,500
IPO [Member]
Offering cost from sale of stock	1,061,157
Over-allotment Option [Member]
Offering cost from sale of stock	$ 1,115,294

Statements of Cash Flows

Statements of Cash Flows - USD ($)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Statement of Cash Flows [Abstract]
Net loss		$ (12,097,479)	$ (3,617,022)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation		11,415	7,731
Stock-based compensation		279,508	94,094
Amortization of debt discount		17,765	5,347
Debt discount on convertible notes		5,172,000
Inventory reserve		42,355
Common stock issued for services and software license		31,845
Change in fair value of derivative liabilities		(116,795)
Changes in operating assets and liabilities:
Accounts receivable		(182,533)	1,136
Inventories		(161,075)	120,588
Prepaid expenses and other		(235,938)	(38,461)
Restricted cash			(52,000)
Deferred offering costs			(431,961)
Accounts payable and other accrued expenses		563,225	364,165
Accrued interest		377,503	299,175
Deferred revenue		144,785	44,538
Net cash used in operating activities		(6,153,419)	(3,202,670)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment		(67,002)	(1,865)
Net cash used in investing activities		(67,002)	(1,865)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from IPO, net of offering costs	[1]	4,368,315
Proceeds from private placement, net of offering costs		2,922,885
Proceeds from FPO, net of offering costs		10,407,706
Proceeds from convertible promissory notes, net		1,770,000	2,956,218
Repayment of note payable, MLSC		(1,215,900)
Proceeds from exercise of stock options		26,954	2,873
Proceeds from exercise of warrants		102,660
Net cash provided by financing activities		18,382,620	2,959,091
Net increase (decrease) in cash and cash equivalents		12,162,199	(245,444)
Cash and cash equivalents, beginning of period		797,174	1,042,618
Cash and cash equivalents, end of period		12,959,373	797,174
SUPPLEMENTAL DISCLOSURE CASH FLOW INFORMATION
Cash paid during the period for interest		97,099	37,619
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of accrued interest to principal		21,916	443,984
Exchange of 2015 convertible promissory notes for 2016 convertible promissory notes		430,000
Accretion of convertible preferred stock to redemption value		274,011	$ 108,739
Conversion of convertible preferred stock into common stock		12,946,252
Conversion of convertible promissory notes and accrued interest into common stock		5,467,389
Issuance of selling agent warrants in connection with IPO		156,725
Deferred offering costs to additional paid-in capital upon IPO closing	[1]	438,237
Common stock issued for repayment of promissory notes and related accrued interest		$ 1,217,172
[1]	IPO gross proceeds of $4,991,236 are reduced by $622,921 of IPO offering costs that were incurred in 2017. Another $438,237 of IPO deferred offering costs were paid for in 2016.

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Cash Flows [Abstract]
IPO gross proceeds	$ 4,991,236
IPO offering costs	$ 622,921
IPO deferred offering costs		$ 438,237

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® Initial Public Offering under Regulation A and Private Placement under Regulation D On June 9, 2017, the Company completed its initial public offering (“IPO”) under Regulation A of the Securities Act of 1933, as amended, raising $4,991,235, before selling agent and other offering expenses of $1,061,157, through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. On June 9, 2017, the Company also closed on a private placement under Regulation D Rule 506(b) pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consisted of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share. The combined aggregate gross proceeds raised were $7,916,620. In connection with the closing of the Company’s IPO on June 9, 2017, the Company filed an amended and restated certificate of incorporation and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on October 23, 2016. Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001. Follow-on On December 4, 2017, the Company completed a follow-on

Going Concern and Management's

Going Concern and Management's Plan	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Going Concern and Management's Plan	Note 2 — Going Concern and Management’s Plan The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company incurred a net loss of approximately $12.1 million and $3.6 million during the years ended December 31, 2017 and 2016, respectively, and has an accumulated deficit of approximately $35.0 million and $22.9 million at December 31, 2017 and 2016, respectively. Cash used in operating activities was approximately $6.2 million and $3.2 million for the years ended December 31, 2017 and 2016, respectively. The ability of the Company to continue as a going concern is dependent upon achieving a profitable level of operations and the ability of the Company to obtain necessary financing to fund ongoing operations. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance of these financial statements. Historically, the Company has financed its operations through equity and debt financing transactions and expects to continue Management plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern are primarily focused on raising additional capital in order to meet its obligations and execute its business plan by pursuing its product development initiatives and penetrate markets for the sale of its products. Management believes that the Company has access to capital resources through possible public or private equity offerings, exercises of outstanding warrants, debt financings, or other means; however, the Company cannot provide any assurance that it will be able to raise additional capital or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. There can be no assurance the Company will be successful in implementing its plans to alleviate substantial doubt.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Reverse Stock Split On December 20, 2016, the Company filed with the State of Delaware the Seventh Amended and Restated Certificate of Incorporation for a one-for Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at December 31, 2017. As of December 31, 2016, the Company had no cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for doubtful accounts based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. No allowance for doubtful accounts was necessary at December 31, 2017 and 2016. Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is determined using a specific identification method. The Company reduces the carrying value of inventory for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors. In addition, the carrying value of consigned inventories is reduced by the value of MyPro devices that will not be sold based on historical experience. Restricted Cash Restricted cash consisted of cash deposited with a financial institution as collateral for Company credit cards for sales personnel. Deferred Offering Costs Deferred offering costs are comprised of direct incremental legal, accounting and financial advisor fees related relating to capital raising efforts. Deferred offering costs are offset against proceeds of an offering. In the event a capital raising effort is terminated, deferred offering costs are expensed. Equipment Equipment is stated at historical cost, net of accumulated depreciation and is depreciated using the straight-line method over the estimated useful lives of the related assets, generally three years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. Impairment of Long Lived Assets The Company assesses the recoverability of its long-lived assets, including equipment when there are indications that the assets might be impaired. When evaluating assets for potential impairment, the Company compares the carrying value of the asset to its estimated undiscounted future cash flows. If an asset’s carrying value exceeds such estimated cash flows (undiscounted and with interest charges), the Company records an impairment charge for the difference. Based on its assessments, the Company did not record any impairment charges for the years ended December 31, 2017 and 2016. Demonstration and Test Units Demonstration units represent units provided to customers by the Company for marketing and patient evaluation purposes. These units are manufactured by the Company and are recorded at cost in the statements of operations as part of selling, marketing and general administrative expense. During the years ended December 31, 2017 and 2016, respectively, the Company charged to operations approximately $26,900 and $22,900, respectively, of these units. Test units represent units provided to research and development staff to use in their development process and to end users who are given free units to act as testers so that research and development staff can evaluate and understand their use by patients. A primary objective of these units is to determine when and under what conditions they fail, at which time they are analyzed for cause of failure and then scrapped. These units are recorded at cost in the statements of operations as part of research and development expense. During the year ended December 31, 2017 and 2016 the Company charged to operations approximately $29,200 and $48,000, respectively, of these units. Accounts Payable and Other Accrued Expenses: 2017 2016 Trade payables $ 264,890 $ 311,085 Accrued compensation and benefits 642,425 221,630 Accrued directors fees 100,000 — Accrued offering costs — 77,326 Other 269,921 103,969 $ 1,277,236 $ 714,010 Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity under U.S. GAAP when determining the classification and measurement of its convertible preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as permanent equity. The Company’s preferred shares at December 31, 2016 featured certain redemption rights that were considered by the Company to be outside the Company’s control. Accordingly, the Series A-1 B-1 As of the issuance date, the carrying amount of the Preferred Stock was less than the redemption value. If the Preferred Stock is redeemable at the investor’s option, the carrying value would be increased by periodic accretions so that the carrying value would equal the redemption amount at the earliest redemption date. Such accretion would be recorded as a preferred stock dividend. Derivative Liabilities The Company accounts for warrants determined to be derivative financial instruments by recording the warrants as a liability at fair value and marks-to-market Revenue Recognition The Company derives revenue primarily from the sale of its products to orthotics and prosthetics practices, as well as Veteran Administration and other hospitals and, beginning in 2017, through a distribution agreement with Ottobock. The Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable, and collectability is deemed probable. In certain cases, the Company ships the MyPro device to O&P practices pending reimbursement from third party payors. As a result of this arrangement, elements of the revenue recognition criteria have not been met upon shipment of the MyoPro. The Company recognizes revenue when payment has been received, as all of the revenue recognition criteria has been met. During 2017, effective with its introduction of its extended product line, the Company provides a standard three-year warranty. This revenue is recognized ratably over the warranty period. The Company allocates revenue to the warranty element of a sale based upon its fair value as determined by referencing the historical selling price of it in similar transactions. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies. As such, we have delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The Company receives federally-funded grants that require the Company to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. The Company’s grant revenue is recognized when persuasive evidence of the arrangement exists, the service has been provided and adherence to specific parameters of the awarded grant have been met, the amount is fixed and determinable and collection is reasonable assured. The Company recognized approximately $118,100, $20,800 and $131,900, respectively, of grant income in 2017, 2016 and 2015, respectively. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Cost of revenue includes reimbursable costs of approximately $11,600 and $10,100 in 2017 and 2016, respectively. Amounts received in advance are deferred. Shipping and Handling Costs Shipping and handling costs paid by customers are netted against the related shipping costs we incur. The net cost is recorded in cost of sales. Historically, such costs have not been material. Income Taxes The Company accounts for income taxes under Accounting Standards Codification ASC 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the financial statement in the period in which the law is enacted. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows. The Company files income tax returns in federal and state jurisdictions and is no longer subject to examinations by tax authorities for years prior to 2014. Currently, there are no income tax audits in process. Stock-Based Compensation The Company accounts for stock awards to employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Options and warrants granted to consultants and other non-employees Stock-based compensation expense of approximately $279,500 and $94,100 was recorded in selling, general and administrative expense in 2017 and 2016, respectively. Net Loss per Share Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the years ended December 31, 2017 and 2016, respectively, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potentially common shares issuable at December 31, 2017 and 2016 consist of: 2017 2016 Options 369,004 246,344 Warrants 6,277,443 10,781 Series B-1 — 1,662,104 Series A-1 — 960,083 Total 6,646,447 2,879,312 Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $31,000 and 41,600 in 2017 and 2016, respectively. Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs primarily consist of salaries and benefits, facility and overhead costs, and outsourced research activities. Reclassification Certain amounts in the 2016 financial statements of operations have been reclassified to conform to the 2017 presentation. These reclassifications had no impact on previously reported net loss. Subsequent Events The Company evaluates events and/or transactions occurring after the balance sheet date and before the issue date of the financial statements to determine if any of those events and/or transactions require adjustment to or disclosure in the financial statements. Revision of Financial Statements During the preparation of its Offering Circular Supplement for the quarterly period ended March 31, 2017, the Company determined it had improperly classified its Notes Payable, MLSC and certain related accrued interest as long-term liabilities, which resulted in an understatement of current liabilities as of December 31, 2016. The Company assessed the materiality of the misstatement in accordance with Staff Accounting Bulletin No. 99, “Materiality” and No. 108, “Quantifying Misstatements”, and concluded that these classification errors were not qualitatively material and there was no impact on the Company’s condensed statements of operations, cash flows, changes in redeemable and convertible preferred stock and stockholders’ equity (deficiency) and net loss per share for the years then ended, nor on the Company’s stockholders’ equity (deficiency). As such, the correction of the error is reflected in the December 31, 2016 balance sheet. Disclosure of the revised amounts will also be reflected in future filings containing the applicable periods. The effect of this revision on the line items within the Company’s balance sheet as of December 31, 2016 was as follows: December 31, 2016 As previously Adjustment As revised Total current liabilities $ 1,807,311 $ 1,193,984 $ 3,001,295 Non-current 4,709,156 (1,193,984 ) 3,515,172 Total liabilities $ 6,516,467 $ — $ 6,516,467 Recent Accounting Pronouncements Revenue Related Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, 2014-09”). 2014-09 2014-09 2014-09 No. 2015-14, No. 2014-09 ASU 2014-09 2016-08 In March 2016, the FASB issued ASU No. 2016-08, ASU No. 2014-09 — 2014-09, ASU 2016-08 On May 2016, the FASB issued ASU No. 2016-12, (“ASU 2016-12”). 2016-12 2014-09. 2014-09, In September 2017, the FASB issued ASU No. 2017-13, The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies. As such, the Company has delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. Other Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, 2016-02”). 2016-02 ASU 2016-02 ASU 2016-02 2016-02 In March 2016, the FASB issued ASU No. 2016-09, In August 2016, the FASB issued ASU 2016-15, 2016-15 In November 2016, the FASB issued ASU 2016-18, 2016-18 In May 2017, the FASB issued ASU No. 2017-09, 2017-09 In July 2017, the FASB issued ASU No. 2017-11, No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11. 2017-11 Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	Note 4 — Inventories Inventories consist of the following at December 31: 2017 2016 Finished goods $ 122,000 $ 81,223 Consigned inventory 97,980 — Parts and components 23,530 1,213 243,510 82,435 Less: excess and obsolete inventory reserves (23,739 ) — Less: consigned inventory reserves (18,616 ) — Inventories, net $ 201,155 $ 82,435 Consigned inventory represents products that have been delivered for which the Company does not have the right to bill. At December 31, 2017, the Company has recorded reserves for consigned inventory for units that will not sold based on historical experience. At December 31, 2017, as a result of its introduction of its MyoPro 2 products, the Company recorded excess and obsolete inventory reserves of $23,700.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Equipment	Note 5 — Equipment Equipment consists of the following at December 31: 2017 2016 Computer equipment $ 32,257 $ 19,258 Sales demonstration units 54,003 — R&D tools and molds 22,650 22,650 108,910 41,908 Less: accumulated depreciation (31,760 ) (20,345 ) Equipment, net $ 77,150 $ 21,563

Revolving Line of Credit

Revolving Line of Credit	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Revolving Line of Credit	Note 6 — Revolving Line of Credit On June 8, 2017, the Company’s Chairman, President, and Chief Executive Officer, entered into an agreement with the Company pursuant to which he committed irrevocably to establish an up to $1,000,000 revolving line of credit for the Company. This commitment is subject to the preparation, execution and delivery of definitive loan documentation in customary form, including note(s) incorporating substantially the terms and conditions set forth in the accompanying term sheet. The line of credit will bear an interest rate of 10% of per annum and will terminate upon the earlier of (i) December 31, 2018; and (ii) the Company entering into a debt or loan facility with a bank or non-bank On December 20, 2017, after completion of our recent FBO which resulted in gross proceeds of $11.5 million, the Company’s Board of Directors determined that having this line of credit available was no longer needed. It was determined not to prepare definitive documents for this line of credit and to cancel it. Accordingly, on this date the Company canceled the line of credit.

Notes Payable, MLSC

Notes Payable, MLSC	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Notes Payable, MLSC	Note 7 — Notes Payable, MLSC Notes payable, MLSC represent promissory notes in the aggregate amount of $750,000 entered into with the Massachusetts Life Sciences Center (“MLSC”). The promissory notes are unsecured and bear interest at the rate of 10% per annum. The principal and accrued interest is due and payable upon the earlier of (i) June 7, 2016, (ii) the closing of a Qualified Financing in a single transaction or series of transactions in any 12 month period yielding net proceeds of at least $5,000,000 or a qualified sale, as defined in the promissory notes, or (iii) the occurrence of a default, as defined in the promissory notes. In addition, in connection with the issuance of the promissory notes to MLSC, the Company issued warrants that are exercisable immediately at the election of the holder on a net share cashless basis or for $30,000 as calculated in the formula defined in the agreement ($750,000 aggregate principal amount multiplied by 4%). The warrants have a life of 10 years. On the date of issuance the maximum number of shares of stock to be acquired under the warrants is determined by the formula and amounted to 4,637 shares. The holder of the warrant has the option to exercise into equity instruments (“Alternative Securities”) of the Company under the following four scenarios: 1) for common stock at the exercise price equal to $2,500,000 divided by the number of shares of common stock outstanding on the issuance date of the warrants; or 2) for common stock during the ten-year 3) for any class or series of preferred stock sold by the Company during the ten-year 4) for the equity interests sold in a qualified financing (as defined) during the ten-year The Company accounted for the issuance of the note in accordance with ASC 815 “Derivatives and Hedging”. The warrants have a feature that included a reset provision considered to be a down-round protection. Accordingly, the warrants were recorded as derivative liabilities at fair value and are marked to market through earnings at the end of each reporting period. The gross proceeds from the issuance of the note are recorded net of a discount and is charged to interest expense ratably over the term of the note. On the date of issuance the debt discount was deemed to be immaterial. On May 18, 2016, the Company restructured its promissory note with MLSC, extending the maturity date to June 7, 2017. The outstanding principal amount of the note now includes the principal amount and all accrued but unpaid interest thereon in the amount of approximately $1,194,000. The note bears interest at 10% per annum with accrued interest payable quarterly which began on September 30, 2016, and is secured by substantially all the Company’s assets. The Company did not recognize a gain or loss with the modification of the extension date of this note and no other terms of the notes changed. On June 6, 2017, the Company restructured its promissory note with MLSC, extending the maturity date to June 7, 2017. The outstanding principal amount of the note now includes the principal amount and all accrued but unpaid interest thereon in the amount of approximately $1,216,000. . The note bears interest was reduced to 7% per annum with approximately $54,000 in interest payable monthly beginning on June 7, 2019 with the principal and any remaining unpaid accrued interest due the earlier of June 7, 2019, or Company completes an equity financing in any twelve-month period raising an aggregate of $10 million in gross proceeds (a “Qualified Financing”), excluding the conversion into common stock in an initial public offering of any convertible notes outstanding on the date of this amendment. In such case, these notes become due within 30 days of the completion of the financing. The Company did not recognize a gain or loss with the modification of the notes. On June 9, 2017, Myomo closed on its IPO and concurrent private placement that met the amended definition of a Qualified Financing included the warrants. Accordingly, the warrants were no longer convertible into Alternative Securities at a floating price and the aggregate warrant shares became fixed at 4,637 and the exercise price became fixed at the weighted average offering price of $6.47 per share. On December 13, 2017, the Company repaid MLSC all outstanding principal and accrued but unpaid interest, totaling $874,600. The repayment satisfied all outstanding obligations under this note.

Notes Payable, Shareholder

Notes Payable, Shareholder	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Notes Payable, Shareholder	Note 8 — Notes Payable, Shareholder Notes payable, shareholder represents promissory notes in the aggregate amount of approximately $580,800 entered into with one of the Company’s shareholders. The promissory notes were unsecured, bore interest at a rate of 10% per annum, and were set to mature on May 25, 2016 at which time principal and accrued interest was due and payable. In addition, in connection with the issuance of the promissory notes to a shareholder, the Company issued warrants that are exercisable immediately at the election of the holder on a net share cashless basis or for cash totaling $23,232 ($580,800 aggregate original principal amount of notes multiplied by 4%) as calculated in the formula defined in the agreement. The warrants have a life of 10 years. On the date of issuance the maximum number of shares of stock to be acquired under the warrants is determined by the formula and amounted to 4,706 shares. The holder of the warrant has the option to exercise into equity instruments (“Alternative Securities”) of the Company under the following four scenarios: 1) for common stock at the exercise price equal to $2,500,000 divided by the number of shares of common stock outstanding on the issuance date of the warrants; or 2) if during the ten-year 3) for any class or series of preferred stock sold by the Company during the ten-year 4) for the equity interests sold in a qualified financing (as defined) during the ten-year The Company accounted for the issuance of the notes in accordance with ASC 815 “Derivatives and Hedging”. The warrants have a feature that included a reset provision considered to be a down-round protection. Accordingly, the warrants were recorded as derivative liabilities at fair value and are marked to market through earnings at the end of each reporting period. The gross proceeds from the sale of the note are recorded net of a discount and is charged to interest expense ratably over the term of the note. On the date of issuance the debt discount was deemed to be immaterial. On September 1, 2015, the Company reached an agreement with the shareholder to modify the terms of the promissory notes. The promissory notes were amended and restated to include approximately $295,700 of accrued and unpaid interest resulting in a total principal amount of approximately $876,500. The amended and restated promissory notes are unsecured, bear interest at a rate of 10% per annum, and mature on August 1, 2018. Any accrued and unpaid interest through September 1, 2016 was converted into principal. The promissory notes required monthly payments of principal and interest in the aggregate amount of approximately $44,500 commencing on September 1, 2016 through August 1, 2018. The Company did not recognize a gain or loss with the modification of this note. On June 29, 2016, prior to the maturity date, the Company reached an agreement with a shareholder to modify the terms of its promissory notes from the Company. The amended and restated promissory notes are unsecured, bear interest at a rate of 10% per annum, and are subordinated to the Note Payable, MLSC and the Company’s convertible subordinated promissory notes. The outstanding principal and any accrued but unpaid interest shall be due and payable upon the earlier of (i) June 7, 2017 or (ii) within 30 days following the closing of a Qualified Financing, as defined. In the event of a closing of a Qualified Financing, the Company may elect, in its sole discretion, to repay up to 50% of the outstanding principal and any accrued but unpaid interest as shall be due and payable under this note as of the date of the Qualified Financing by issuing shares of the Company’s equity issued in the Qualified Financing, equal to 80% of the price per share paid by the purchasers of such equity in the Qualified Financing. The Company did not recognize a gain or loss with the modification of this note. On May 23, 2017, Myomo and a related party noteholder entered into an agreement to amend Myomo’s related party promissory notes. The maturity date was extended from June 8, 2017 to June 8, 2019, unless prior to that date, the Company completes an equity financing in any twelve-month period raising an aggregate of $10 million in gross proceeds (a “Qualified Financing”), excluding the conversion into common stock in an initial public offering of any convertible notes outstanding on the date of this amendment. In such case, these notes become due within 30 days of the completion of the financing. The Company may elect, in its sole discretion, to repay up to 50% of the outstanding principal and any accrued but unpaid interest as shall be due and payable under this note by issuing shares of the Company’s equity equal to 80% of the price per share of common stock. The Company did not recognize a gain or loss with the modification of the note. The conversion price modification is contingent on the price of the IPO and any charge will be recorded on the date of the IPO. On June 9, 2017, Myomo closed on its IPO and concurrent private placement that met the amended definition of a Qualified Financing included the warrants. Accordingly, the warrants were no longer convertible into Alternative Securities at a floating price and the aggregate warrant shares became fixed at 3,591 and the exercise price became fixed at the weighted average offering price of $6.47 per share. The Company was notified in October 2017 that the noteholder liquidated all of its outstanding common stock. As of September 30, 2017, the Noteholder is no longer a related party. On November 13, 2017, the Company and the Noteholder entered into an agreement to further modify the terms of its promissory notes from the Company. Pursuant to the note amendments, the Company may elect, in its sole discretion, if its common stock is then-traded on the NYSE American or another stock exchange or over-the-counter On November 13, 2017, the Company repaid the Noteholder all outstanding principal and accrued but unpaid interest under the notes, totaling approximately $1,081,135 in cash by issuing 107,505 shares of the Company’s common stock at a price per share equal to $5.03, 80% of the price per share of common stock on the repayment date, and issuing 86,004 shares of the Company’s common stock at a price per share equal to $6.29, the price per share of common stock on the repayment date. In conjunction with this repayment, the Company recorded a $135,244 loss on early extinguishment of debt in the fourth quarter of 2017.

Convertible Promissory Notes 20

Convertible Promissory Notes 2016	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Convertible Promissory Notes 2016	Note 9 — Convertible Promissory Notes 2016 During the year-ended December 31, 2016, the Company issued convertible promissory notes (Notes) with an aggregate principal balance of $2,372,000 as of December 31, 2016. The Notes bear an interest rate of 8% per annum and mature on December 31, 2018, at which time the principal and any accrued but unpaid interest will be due and payable on demand. The Notes are subordinated to notes payable, MLSC. In the event the Company consummates, prior to the Maturity Date, an equity financing pursuant to which the Company sells common stock, preferred stock or other equity or equity-linked securities with aggregate gross proceeds of not less than $5 million, excluding any and all indebtedness under the Notes that is converted into equity securities of the Company, the outstanding principal of the Notes and any accrued but unpaid interest will be converted into the equity securities upon the closing of the Next Equity Financing, as defined, yielding gross proceeds of at least $5,000,000. The number of shares of equity securities of the Company to be issued upon such conversion shall be equal to the quotient obtained by dividing the entire principal amount plus accrued interest by the lower of (i) a price per share equal to $35,000,000 divided by the aggregate number of shares of capital stock outstanding on a fully diluted basis immediately prior to the initial closing of the Qualified Financing, as defined, and (ii) eighty percent (80%) of the price per share of the equity securities being sold. In the event of a sale of the Company, as defined, prior to the conversion or repayment in full of these notes, a cash payments will be made equal to the aggregate amount of principal and accrued, but unpaid, interest then outstanding under these notes. In addition, an amount equal to 25% of the original principal amount of the notes will be paid to the note holder as a “Sale Premium”. In connection with the issuance of the convertible promissory notes, the Company issued warrants to purchase common stock to the holders of the new convertible promissory notes. The number of shares of stock to be acquired under the warrants, after this additional issuance is determined by a formula which amounts to 100% of the principal amount invested divided by the lowest price paid per share for the equity securities by the investors in the Next Equity Financing. In accordance with ASC 470-20-25-20 As of December 31, 2016, the Company had capitalized deferred issuance costs of $20,800 relating to 2016 convertible promissory notes and had amortized $3,000 to interest expense in the statements of operations. Debt issuance costs are comprised of incremental legal and accounting fees related to the issuance of convertible promissory notes. Debt issuance costs are amortized over the life of the related debt instrument. Net debt issuance costs are included in the balance sheets as a reduction (debt discount) of the related convertible promissory notes. On October 3, 2016, the Company modified the terms of the 2016 Convertible Note Offering (issued beginning in June 2016) such that the automatic conversion of the Notes will additionally require that the Next Equity Financing be a public equity financing. In addition, the prepayment terms of the Notes were modified such that consent of the holder of the Note is required for any prepayment, in whole or in part, by the Company, and the Company is obligated to offer to the holders of all other then-outstanding Notes the opportunity to be prepaid on the same terms and conditions. Finally, the Sales Premium, 25% of the original principal amount of the Notes, was modified such that if the amount that a Holder would have received upon the repayment of the Note upon a Sale of the Company, including the Sales Premium, is less than the amount that the Holder would have received if it had converted into shares of Common Stock the outstanding principal amount plus accrued but unpaid interest on the Note divided by the Capped Conversion Price, as defined, immediately prior to the Sale of the Company, then the Note shall automatically convert into shares of Common Stock in accordance with such formula. On October 12, 2016, the Company issued a Note in the original principal amount of $1,000,000 to one Holder on such modified terms. The Company offered the then other Holders the right to exchange their original Notes for Notes with such modified terms. Since a majority of the other Holders approved the new terms, under the terms of the notes, the Company has issued to all Holders amended and restated notes with the modified terms to replace the terms of the original notes. The Company did not recognize a gain or loss with the modification of the notes. As of December 31, 2016, as described in Note 10, $630,000 of Convertible Promissory Notes 2015 was exchanged for these notes, resulting in a total of $3,002,000 outstanding as of December 31, 2016. During the three months ended March 31, 2017, the Company issued additional the 2016 convertible promissory notes with an aggregate principal balance of $1,770,000 for cash. In addition, during this period the Company entered into an agreement with certain 2015 convertible promissory noteholders whereby the noteholders of the 2015 convertible promissory noteholders exchanged $430,000 notes for an equivalent amount of 2016 convertible promissory notes (See Note 10). The Company did not recognize a gain or loss on the exchange of the notes. The 2016 convertible promissory notes had an interest rate of 8% per annum and were to mature on December 31, 2018, at which time the principal and any accrued but unpaid interest would be due and payable on demand. The notes were subordinated to the notes payable, MLSC. The 2016 convertible promissory notes provided that in the event the Company, on or before the date of the repayment in full of these notes, sells shares of its equity securities to investors in any public equity financing resulting in gross proceeds to the Company of at least $5 million (excluding the conversion of these convertible promissory notes and any other indebtedness, but including, for such purposes, all amounts raised in the Company’s initial public offering, then the outstanding principal balance of these notes, and any accrued but unpaid interest will be automatically converted into the equity securities upon the closing of the initial public offering. The number of shares of equity securities of the Company to be issued upon such conversion shall be equal to the quotient obtained by dividing the entire principal amount plus accrued interest by the lower of (i) a price per share equal to $35,000,000 divided by the aggregate number of shares of capital stock outstanding on a fully diluted basis immediately prior to the initial closing of the Qualified Financing, as defined, and (ii) eighty percent (80%) of the per share price paid by the Investors in the Qualified Financing. The Company did not record a gain or loss for the exchange. The modification was deemed to be a contingent conversion price adjustment and would only be recognized when the triggering event occurs (i.e. the IPO). On June 5, 2017, the Company modified the terms of these 2016 convertible promissory notes such that the automatic conversion of these notes will occur upon any public equity financing resulting in gross proceeds to the Company of at least $5,000,000, excluding the conversion of the notes and any other indebtedness, but including, for such purposes, all amounts raised in the IPO and the concurrent private placement. . The Company did not record a gain or loss for the modification of the notes. The modification was deemed to be a contingent conversion price adjustment and would only be recognized when the triggering event occurs (i.e. the IPO). Upon the closing of the Company’s IPO on June 9, 2017, in accordance with the terms of the 2016 convertible promissory notes, the principal balance of these notes, and all accrued but unpaid interest, totaling $5,467,389 were converted into 1,055,430 shares of common stock at weighted-average price of $5.18 per share. In connection with the issuance of the 2016 convertible promissory notes, the Company issued, to these noteholders, warrants to purchase common stock which are exercisable for three years from the date of the IPO. One warrant was issued for each share of common stock issued as part of the conversion. Upon the closing of the IPO, the warrants became exercisable and the warrant terms became fixed, such that at September 30, 2017, there were warrants outstanding to purchase 799,349 shares of common stock exercisable at $6.47 per share. As of the IPO date, the Company determined that the relative fair value of the warrants attributable to 2016 convertible promissory note holders (excluding those issued in conjunction with the exchange of the 2015 convertible promissory notes) was $1,628,006. In accordance with ASC 470-20-25-20 The Company had capitalized deferred issuance costs of approximately $20,800 relating to 2016 convertible promissory notes and had amortized approximately $6,700 to interest expense in the statements of operations through the date of its IPO. Debt issuance costs are comprised of incremental legal and accounting fees directly related to the issuance of convertible promissory notes. Debt issuance costs are amortized over the life of the related debt instrument. Net debt issuance costs are included in the balance sheets as a reduction (debt discount) of the related convertible promissory notes prior to the closing of the Company’s IPO.

Convertible Promissory Notes 18

Convertible Promissory Notes 2015	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Convertible Promissory Notes 2015	Note 10 — Convertible Promissory Notes 2015 The Company issued convertible promissory notes with an aggregate principal balance of $425,000 in 2015 and an additional $605,000 in 2016, for a total of $1,030,000. The notes are subordinated to the Note Payable, MLSC, bear interest at a rate of 8% per annum, and mature in December 2017. Prior to December 2017 and at the option of the holders of the convertible promissory notes, the outstanding principal, and any accrued, may be converted into equity securities of the Company upon the closing an equity financing, as defined, yielding gross proceeds of at least $5,000,000. The outstanding principal balance and any accrued interest are convertible into shares of equity securities sold in the next equity financing at a price per share equal to 85% of the lowest price per share during the equity financing. In addition, the holders of the notes are entitled to an additional payment equal to 10% of the original principal amount of the convertible promissory notes if held on the maturity date. In connection with the issuance of the convertible promissory notes, the Company issued warrants to purchase common stock that are exercisable at any time beginning on the date of a future equity financing, as defined in the agreement, and ending on the five year anniversary thereof. The number of shares of stock to be acquired under the warrants is determined by a formula which equals 15% of the amount invested divided by the lowest price paid per share for the equity securities by the investors in the equity financing as defined in the agreement. In accordance with ASC 470-20-25-20 During the fourth quarter of 2016, the Company offered the Holders of its 2015 Convertible promissory notes (issued from December 2015 through April 2016) the right to exchange their notes for 2016 Convertible Notes by cancelling an equivalent amount of outstanding existing notes. These 2016 Convertible Notes were issued on otherwise the same terms and conditions as the participants in the 2016 Convertible Notes offering who paid the purchase price in cash. Holders of the prior notes were able to also retain the warrants issued to them in conjunction with the prior notes. As of December 31, 2016, an aggregate of $630,000 of Prior Notes were cancelled in exchange for the issuance of an equivalent principal amount of new notes in the financing. Subsequent to December 31, 2016, the holders of $400,000 of Prior Notes agreed to exchange their Prior Notes; therefore the remaining Prior Notes were cancelled in exchange for the issuance of an equivalent principal amount of new notes in the financing. The Company did not recognize a gain or loss the exchange of the notes. For the three months ended March 31, 2017, the noteholders exchanged $430,000 of their 2015 Convertible Promissory Notes for 2016 convertible promissory notes of an equivalent principal amount. The other 2015 Convertible Promissory Notes that were previously outstanding had been exchanged for 2016 convertible promissory notes of an equivalent principal amount in 2016. The Company did not recognize a gain or loss the exchange of the notes. (See Note 9). In connection with the issuance of the 2015 convertible promissory notes, the Company agreed to issue warrants to purchase common stock to these noteholders, which are exercisable for five years from the date of the IPO. The number of shares of stock to be acquired under the warrants is determined by a formula which amounts to 15% of the principal amount invested divided by the lowest price paid per share for the equity securities by the investors in the Equity Financing as defined. Upon the closing of the IPO, the Company issued warrants to purchase 29,425 shares of common stock exercisable at $5.25 per share. All warrants issued were outstanding at September 30, 2017. As of the IPO date, the Company determined that the relative fair value of the warrants attributable to original 2015 convertible promissory note holders (including those issued in conjunction with the exchange into the 2016 convertible promissory notes) was $457,456. In accordance with ASC 470-20-25-20

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 11 — Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices available in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The carrying amounts of the Company’s financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents are a money market fund that limits its investments to only short-term U.S. Treasury securities and repurchase agreements related to these securities. The carrying amounts of the Company’s notes payables approximates fair value, as the notes include contractual interest rates, taken together with other features such as concurrent issuance of warrants, which are comparable to rates of returns for instruments of similar credit risk. Cash equivalents and derivative liabilities (see Note 17) measured at fair value on a recurring basis at December 31, 2017 were as follows: In Active Markets Significant Other Significant December 31, Cash equivalents $ 10,459,435 — — $ 10,459,435 Common stock warrant liabilities — — $ 39,930 $ 39,930 There were no cash equivalents at December 31, 2016 and derivative liabilities measured at fair value on a recurring basis were nominal. The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the year ended December 31, 2017 and 2016: Common stock Balance – January 1, 2016 $ 2,239 Change in fair value of derivative liabilities (2,329 ) Balance – December 31, 2016 — Fair value of common stock warrant issued 156,725 Change in fair value of derivative liabilities (116,795 ) Balance – December 31, 2017 $ 39,930 Assumptions utilized in the valuation of Level 3 liabilities at December 31, were as follows: 2017 2016 Risk-free interest rate 2.20% — Expected life 4.44 years — Expected volatility of underlying stock 63% — Expected dividend yield — — The expected stock price volatility for the Company’s common stock warrant liabilities was determined by the historical volatilities for industry peers and used an average of those volatilities. Risk free interest rates were obtained from U.S. Treasury rates for the applicable periods. The expected term used is the contractual life of the instrument being valued. The expected dividend yield was not considered in the valuation of the common stock liabilities as the Company has never paid, nor has the intention to pay, cash dividends.

Fair Value of Common Stock Dece

Fair Value of Common Stock December 31, 2016	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Common Stock December 31, 2016	Note 12 — Fair Value of Common Stock December 31, 2016 The Company accounts for equity-based compensation in accordance with the fair value provisions of ASC Topic 718. Until the Company’s IPO on June 9, 2017, the Company’s common stock was not listed on any exchange and, accordingly, the Company hired an independent valuation specialist to assist the Company in arriving at an estimated fair value of the Company’s outstanding securities as of December 31, 2016. The Company, with the assistance of an independent appraiser, considered the following factors in preparing its fair value analyses of the common stock as of December 31, 2016: • Changes in and uncertainties with respect to, regional, national and international economic conditions; • The Company’s Enterprise Value using a similar transactions method; • The Company’s ability to access the debt and equity capital markets; • Other relevant factors such as control premiums or discounts for lack of marketability. The Company used the discounted cash flow method under the income approach to estimate the fair value of the Company’s equity as of December 31, 2016. Equity value was allocated using the OPM. The Company used the OPM to determine the relative fair values of its equity securities. As of December 31, 2016 the significant assumptions used in this model was as follows: 2016 Market value 9.0 million Volatility 81% Time to liquidity 2.0 years Risk free rate 0.58% Discount for lack of marketability 25% The market value of the Company’s equity as of December 31, 2016 was determined using the discounted cash flow method. Equity value was allocated using a hybrid method. A hybrid method is a probability-weighted expected returns method which uses the OPM in at least once scenario. Two scenarios were considered: an OPM and a second scenario in which the Company’s preferred securities convert to common stock in conjunction with a Reg A offering. For the OPM the assumed time-to-liquidity As of December 31, 2016, the fair value of the Company’s outstanding securities was as follows: 2016 Common Stock $ 1.04 Series B-1 $ 4.06 Series A-1 $ 1.25

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Common Stock	Note 13 — Common Stock On June 9, 2017, the Company completed its IPO raising $4,991,235, before selling agent commissions and other offering expenses of $1,061,157, through the sale of 665,498 shares of its common stock at a price of $7.50 per share. On June 9, 2017, the Company also closed on a private placement pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share. Upon the closing of the Company’s IPO on June 9, 2017, in accordance with the terms of the 2016 convertible promissory notes, the principal balance of these notes, and all accrued but unpaid interest, totaling $5,467,389 were converted into 1,055,430 shares of common stock at weighted-average price of $5.18 per share. In connection with the closing of the Company’s IPO on June 9, 2017, the Company filed an amended and restated certificate of incorporation and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on October 23, 2016. Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001. On December 4, 2017, the Company completed a follow-on On November 13, 2017, the Company repaid all outstanding principal and accrued but unpaid interest under certain notes payable, totaling approximately $1,081,135 in cash by issuing 107,505 shares of the Company’s common stock at a price per share equal to $5.03, 80% of the price per share of common stock on the repayment date, and issuing 86,004 shares of the Company’s common stock at a price per share equal to $6.29, the price per share of common stock on the repayment date. During the year ended December 31, 2017 and 2016, the Company issued 80,085 and 124,456 shares of common stock through the exercise of stock options for proceeds of $26,954 and $2,873, respectively. During the year ended December 31, 2017, the Company issued 34,800 shares of common stock through the exercise of warrants for proceeds of $102,660. In June 2017, the Company issued 4,000 shares to an investor relations firm for services performed. The Company recorded a charge to operations for $30,000 for the fair value of the stock issued. At December 31, 2016 the Company has authorized 5,600,000 shares of common stock with a par value of $0.0001 per share, of which 2,622,187 are reserved for issuance in connection with the conversion of Series A-1 B-1 As of December 31, 2016 the Company has outstanding 253,783 shares of restricted common stock previously issued to key executives of the Company. The restricted common stock included provisions for lapsing forfeiture rights that extended up to 48 months. As of December 31, 2016, 2,626 shares of common stock were subject to forfeiture. The stock compensation expense is being amortized over the respective vesting periods. At December 31, 2016, the unamortized stock compensation expense was approximately $2,300 and is expected to be recognized over 0.08 years. The Company recorded a charge of approximately $27,300 for the year ended December 31, 2016. On December 20, 2016, the Company filed with the State of Delaware the Seventh Amended and Restated Certificate of Incorporation for a one-for

Treasury Stock

Treasury Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Treasury Stock	Note 14 — Treasury Stock Treasury stock is reported at cost and consists of 808 shares of common stock as of December 31, 2017 and 2016.

Redeemable Preferred Stock

Redeemable Preferred Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Redeemable Preferred Stock	Note 15 — Redeemable Preferred Stock Upon closing of the IPO, the Company issued 960,083 shares of common stock upon the conversion of 960,083 shares of Series A-1 B-1 The following table below summarizes the authorized, issued and outstanding Preferred Stock as of December 31, 2016: Shares Shares Par Value Cumulative Dividend Liquidation Series B-1 1,862,500 1,662,104 $ 0.0001 $ 1,495,127 $ 0.90 $ 9,701,313 Series A-1 1,594,958 960,083 $ 0.0001 $ — $ — $ 4,740,066 Series B-1 As of December 31, 2016, the Company had issued and outstanding 1,662,104 shares of Series B-1 Conversion Each share of Series B-1 Series B-1 B-1 Series B-1 as-converted On August 23, 2016, the holders of the Company’s preferred stock, voting together as a single class on an as-converted Dividends From and after the date of the issuance of Series B-1 Series B-1 B-1 B-1 B-1 A-1 A-1 as-if-converted Liquidation Preference In the event of any liquidation, dissolution or winding up of Myomo, the holders of the Series B-1 A-1 B-1 B-1 B-1 Series B-1 B-1 The remaining assets available for distribution to the shareholders shall be distributed among the holders of Series A-1 A-1 Redemption The holders of Series B-1 B-1 B-1 B-1 Voting Each holder of Series B-1Preferred B-1 Series A-1 B-1 B-1 Series A-1 As of December 31, 2016, the Company had issued and outstanding 960,083 shares of Series A-1 Conversion Each share of Series A-1 Series A-1 A-1 as-converted On August 23, 2016, the holders of the Company’s preferred stock, voting together as a single class on an as-converted Dividends The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock, including Common Stock (other than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of Series B-1 B-1 Series A-1 A-1 as-if-converted Liquidation Preference The holders of Series A-1 A-1 A-1 B-1 A-1 Series A-1 Redemption The holders of Series A-1 A-1 A-1 A-1 Voting Each holder of Series A-1 A-1 Series B-1 A-1

Stock Award Plans and Stock-bas

Stock Award Plans and Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Award Plans and Stock-based Compensation	Note 16 — Stock Award Plans and Stock-based Compensation Equity Incentive Plan On October 25, 2016, the Company’s shareholders approved the 2016 Equity Incentive Plan (2016 Plan) which became effective on June 9, 2017, the date that the Company completed its IPO. Upon effectiveness of the 2016 Plan, no additional awards have been granted under the Company’s prior equity incentive plans. The Company has reserved 562,500 shares of its Common Stock for issuance under the 2016 Plan. Participation in the 2016 Plan will continue until all of the benefits to which the participants are entitled have been paid in full. At December 31, 2017, there were 377,000 shares available for future grant under the 2016 Plan. In September 2014, the Company established the 2014 Stock Option and Grant Plan and suspended the granting of any new stock awards under the 2004 Stock Option and Incentive Plan, which was established in November 2004. Under the terms of the Stock Plans, incentive stock options (ISOs) may be granted to officers and employees and non-qualified On August 23, 2016, the Company’s shareholders approved an amendment to its 2014 Stock Option and Grant Plan to increase the number of shares of common stock reserved under the plan to an aggregate of 899,549. Stock Option Awards Stock option activity under the Stock Option Plans during the years ended December 31, 2017 and 2016 is as follows: Shares Weighted Weighted Intrinsic Balance at January 1, 2016 272,494 $ 0.1088 6.95 $ 207,146 Granted 101,661 $ 0.9987 Forfeited or cancelled (3,352 ) $ 0.5125 Exercised (124,459 ) $ 0.0259 Balance at December 31, 2016 246,344 $ 0.5133 7.10 $ 132,121 Granted 210,600 $ 2.6568 Forfeited or cancelled (7,855 ) $ 0.9717 Exercised (80,085 ) $ 0.3366 Balance at December 31, 2017 369,004 $ 1.7652 8.65 $ 732,399 Options exercisable at December 31, 2016 140,724 $ 0.3464 5.68 $ 99,879 Options exercisable at December 31, 2017 141,847 $ 0.6906 7.39 $ 433,960 The Company uses the Black-Scholes option pricing model to estimate the grant date fair value of its stock options. There was no income tax benefit recognized in the financial statements for share-based compensation arrangements for the years ended December 31, 2017 and 2016. The weighted-average grant date fair value per share was $1.62 and $0.72 for the years ended December 31, 2017 and 2016, respectively. The assumptions underlying the calculation of grant date fair value are as follows: 2017 2016 Volatility 62.71%-80.00% 81.00% Risk-free interest rate 0.58%-2.29% 0.58% Weighted-average expected option term (in years) 5.75-6.25 5.75-6.25 Dividend yield 0% 0% The stock price volatility for the Company’s options was determined using historical volatilities for industry peers. The risk free interest rate was derived from U.S. Treasury rates existing on the date of grant for the applicable expected option term. The expected term represents the period of time that options are expected to be outstanding. Because the Company has only very limited historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. The expected dividend yield assumption is based on the fact that the Company has never paid, nor has any intention to pay, cash dividends. Restricted Stock Awards On August 15, 2017, the Company granted 46,500 restricted stock awards to certain executives and other managers at an aggregate fair market value on the date of grant of $313,900. The restricted stock awards vest over a period determined by the Company’s Board of Directors, ranging from five months to four years. The Company recorded $123,000 in compensation expense during the year ended December 31, 2017 in connection with the grant of these restricted stock awards. Restricted stock activity is summarized below: Number of Shares Weighted average Weighted average Outstanding as of January 1, 2017 — $ — — Awarded 46,500 6.75 Vested (312 ) 6.75 Canceled (2,000 ) 6.75 Outstanding as of December 31, 2017 44,188 $ 6.75 6.75 Share-Based Compensation Expense The Company attributes the value of stock based compensation, net of estimated forfeitures, to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period. The Company recognized stock-based compensation expense related primarily to the issuance of stock option awards to employees and non-employees 2017 2016 Research and development $ 12,382 $ — Selling, general and administrative 267,126 94,094 Total $ 279,508 $ 94,094 As of December 31, 2017, there was approximately $348,000 of total unrecognized compensation cost related to unvested stock options and is expected to recognized over a weighted-average period of 2.23 years. As of December 31, 2017, there was approximately $177,400 of total unrecognized compensation cost related to unvested restricted stock awards and is expected to recognized over a weighted-average period of 3.63 years.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Warrants	Note 17 — Warrants On June 9, 2017, the Company issued warrants for the purchase of 557,216 shares of common stock to investors in connection with a private placement that closed concurrently with the Company’s IPO, as more fully described in Note 1. The warrants are exercisable for three years from the date of the IPO and are fully vested and exercisable at any time by the holder at a price of $7.50 per share. The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 Derivatives and Hedging the warrants were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. On June 9, 2017, the Company issued warrants for the purchase of 33,275 shares of common stock to its IPO selling agent. The warrants are fully vested, exercisable at any time after December 9, 2017 by the holder at an exercise price of $8.25 per share and have a life of five years. The warrants include a fundamental transaction clause which provides for the warrant holder to be paid in cash upon an event as defined in the warrant. The cash payment is to be computed using the Black-Scholes valuation model for the unexercised portion of the warrant. Accordingly, under ASC 815 Derivatives and Hedging the warrants were deemed to be a derivative liability and are marked to market at each reporting period. Accordingly, on the date of issuance the Company recorded as a derivative liability the fair value of the warrants which was $156,725 and at December 31, 2017 the derivative liability was marked to its then fair market value of $39,930. On December 4, 2017, the Company issued 4,175,000 warrants to purchase shares of its common stock to investors in connection with its FPO, as more fully described in Note 1. The warrants are exercisable at an exercise price of $2.95 per share of common stock, and they expire on December 4, 2022. On December 6, 2017, the Company’s underwriters on its FPO exercised in full their option to purchase 626,250 shares of common stock and accompanying warrant. After giving effect to the full exercise of the over-allotment, the Company issued an aggregate 4,801,250 warrants to purchase an aggregate of 4,801,250 shares of common stock at an exercise price of $2.95 per share of common stock, which expire on December 4, 2022. The early adoption of ASU 2017-11 2017-11, period-to-period. On December 4, 2017, the Company issued warrants for the purchase of 83,500 shares of common stock to the underwriter of its FPO. The warrants are fully vested, exercisable at any time after June 2, 2018 by the holder at an exercise price of $2.40 per share and have a life of three years. . The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 Derivatives and Hedging, they were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. In connection with the issuance of its 2016 and 2015 convertible promissory notes, as more fully described in Notes 8 and 9, the Company issued warrants that expire three years from the date of its IPO for the purchase of 799,349 shares of common stock and warrants that expire five years from the date of its IPO for the purchase of 29,425 shares of its common stock. .The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 Derivatives and Hedging the warrants were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. In addition, in connection with the issuance of its promissory notes to MLSC and a shareholder, as more fully described in Notes 7 and 8, the Company issued warrants that expire in 2021 for the purchase of an aggregate of 8,228 shares of stock at an exercise price of $6.47 per share. The following table presents the Company’s common stock warrant activity for the years ended December 31, 2017 and 2016: Warrants Weighted Average Outstanding Exercisable Outstanding Exercisable Balance, Jan 1, 2016 8,228 8,228 $ 6.47 $ 6.47 Issued — — — — Exercised — — — — Balance, Dec 31, 2016 8,228 8,228 6.47 6.47 Issued 6,304,015 6,220,515 3.84 3.85 Exercised (34,800 ) (34,800 ) 2.95 2.95 Balance, Dec 31, 2017 6,277,443 6,193,943 $ 3.85 $ 3.86 The weighted average remaining contractual life of warrants outstanding and exercisable at December 31, 2017 was 4.37 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 18 — Related Party Transactions The Company sells its products to an orthotics and prosthetics practice whose ownership includes an individual who is both a minority shareholder and employee of the Company. Sales to this related party are sold at standard list prices. During the years ended December 31, 2017 and 2016 revenue recognized on sales to this orthotics and prosthetics practice amounted to approximately $53,500 and $49,100, respectively. Included in accounts receivable at December 31, 2017 and 2016 is approximately $77,600 and $24,500, respectively, and due to the related party. The Company also obtains consulting and fabrication services from the same related party. Charges for these services amounted to approximately $356,400 and $156,900 during the years ended December 31, 2017 and 2016, respectively. Included in accounts payable and accrued expenses at December 31, 2017 and 2016 is approximately $65,800 and $6,600, respectively, due to the related party. Certain directors purchased $1,080,000 of the Company’s subordinated convertible promissory notes in 2016. Certain directors and officers of the Company purchased 142,653 Series B-1 B-1 An officer and director purchased 14,000 shares at $7.50 per share in the Company’s June 9, 2017 IPO. Certain directors and officers of the Company purchased 125,238 shares and 125,238 warrants to purchase shares of common stock, in the Company’s private placement under Regulation D Rule 506(b) that also closed on June 9, 2017, at the price of $5.25 per unit. The warrants are exercisable at an exercise price of $7.50 per share of common stock. Certain directors and officers of the Company purchased 285,000 shares and 285,000 warrants to purchase shares of its common stock in the Company’s FBO, that closed on December, 4, 2017, at the price to the public of $2.40. The warrants are exercisable at an exercise price of $2.95 per share of common stock.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 19 — Commitments and Contingencies Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Currently, there is no litigation against the Company. Operating Leases The Company has a month-to-month Licensing Agreement During 2006, the Company entered into an exclusive licensing agreement for access to certain patent rights that require the payment of royalties, which vary based on the level of the Company’s net sales. As part of the agreement, the Company must pay a nonrefundable annual license maintenance fee which may be credited to any royalty amounts due in that same year. The license agreement can be terminated if certain sales targets are not achieved. The royalty charge for each of the years ended December 31, 2017 and 2016 was $25,000 and is included as a component of cost of sales. The future minimum amounts due under this agreement for the next five years and thereafter are as follows: 2018 $ 25,000 2019 25,000 2020 25,000 2021 25,000 2022 through expiration of the patents 50,000 Under the licensing agreement, the Company has issued 6,172 shares of Common Stock to the licensor, including 492 shares on December 29, 2017, pursuant to a licensing agreement share adjustment provision in the event that the Company has a dilutive financing, as defined. The licensing agreement also includes an anti-dilution provision such that the licensor’s ownership of the outstanding Common Stock shall not fall below 1% on a fully diluted basis. Such issuances of Common Stock continue until the date upon which the Company received a total of $3,000,000 for its capital stock. After t-he On November 15, 2016, the Company and MIT entered into a waiver agreement with regard to certain revenue and commercialization milestones of the Company required under the License Agreement. Under the waiver agreement, MIT waived the compliance with any and all of such milestone obligations prior to the date of the waiver agreement. For the year ended December 31, 2017 the Company met its minimum sales covenant of $750,000. Clinical Research Studies The Company has in-process Warranty Liability The Company accrues an estimate of their exposure to warranty claims based on both current and historical product sales data and warranty costs incurred. The majority of the Company’s current products carry a three-year warranty, but prior to 2017 most products carried a one-year Changes in warranty liability were as follows: 2017 2016 Accrual provided for warranties issued during the period Accrued warranty liability, beginning of year $ 63,147 $ 2,994 Accrual provided for warranties issued during the period 14,867 67,382 Adjustments to prior accruals 570 (3,773 ) Actual warranty expenditures (27,859 ) (3,456 ) Accrued warranty liability, end of year $ 50,725 $ 63,147 Credit Risk Financial instruments that potentially expose the Company to a concentration of credit risk consist primarily of cash, cash equivalents and restricted cash and accounts receivable. The Company maintains its cash, cash equivalents and restricted cash, with balances in excess of federally insured limits, with major financial institutions that management believes are financially sound and have minimum credit risk. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant credit risks related to cash. Major Customers For the year ended December 31, 2017 three customers accounted for approximately 54% (23%-$334,200; 17%-$241,700 and 14%-197,800) For the year ended December 31, 2016 four customers accounted for approximately 64% (23%-$253,300; 14%-$155,800; 14%-$155,000 and 12%-$127,200) of revenues, excluding grant income. As of December 31, 2017 three customers accounted for approximately 55% (26%-$77,640 [related party], 18%-$52,200 and 11%-$32,700) of accounts receivable. As of December 31, 2016 four customers accounted for approximately 80% (23%-$26,100, 23%-$25,700; 21%-$24,500 [related party] and 13%-$15,200) of accounts receivable. Economic Dependence During the years ended December 31, 2017and 2016 the Company contracted the manufacture of its product from one vendor. If the current vendor no longer produces the product, the Company would have to find a new manufacturer.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 20 — Income Taxes The income tax provision (benefit) for the years ended December 31, 2017 and 2016 consist of the following: 12/31/17 12/31/16 U.S. federal Current $ — $ — Deferred (534,000 ) (1,184,000 ) State and local Current — — Deferred ( ) (177,000 ) (1,072,000 ) (1,361,000 ) Deferred tax expense related to tax law change 2,909,000 — Change in valuation allowance (1,837,00 0 ) 1,361,000 Income tax provision $ — $ — The reconciliation between the U.S statutory federal income tax rate and the Company’s effective rate for the years ended December 31, 2017 and 2016 is as follows: 12/31/17 12/31/16 U.S. federal statutory rate 34.00 % 34.00 % State income taxes, net of federal benefit 4.67 % 5.45 % Federal rate change, deferred items -23.03 % 0.00 % State rate change and other 0.89 % -0.54 % Non-deductible -17.67 % — Federal NOLs to expire unutilized due to sec 382 limitation -14.02 % -0.00 % Other permanent items -0.03 % -0.29 % Change in valuation allowance 15.19 % —38.62 % Effective rate 0.00 % 0.00 % As of December 31, 2017, and 2016, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: 12/31/17 12/31/16 Net operating loss carryover $ 5,925,000 $ 7,876,000 Tax credits 190,000 189,000 Stock-based compensation 53,000 19,000 Other 219,000 140,000 Total deferred tax asset 6,387,000 8,224,000 Less: valuation allowance ( ) (8,224,000 ) Deferred tax asset, net of valuation allowance $ — $ — There were no deferred tax liabilities at December 31, 2017 or 2016. As of December 31, 2017 and 2016, the Company had approximately $26.4 million and $20.4 million of Federal net operating loss (“NOL”), and $22.0 million and $16.9 million of state NOLs, respectively, available to offset future taxable income. The Federal NOLs, if not utilized, begin expiring in the year 2028. The state NOLs, if not utilized, begin to expire in 2019 through 2027. During 2017, the Company experienced an ownership change within the meaning of Section 382 of the Internal Revenue Code of 1986. The ownership change has and will continue to subject the Company’s pre-ownership tax-exempt Ownership changes were also determined to have occurred during the third quarter of 2014 and second quarter of 2015. As a result of these ownership changes, the Company is limited to an approximate $1,559,000 annual limitation on its ability to utilize pre-change pre-change On December 22, 2017, the Tax Cuts and Jobs Act (TCIA) was signed into law. The enacted law reduces the corporate tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the period in which the law is enacted. As a result of the enacted law, the Company is required to revalue deferred tax assets and liabilities at the enacted rate and reflect that change in its financial statements for the period that includes the date of enactment, since the deferred tax items would be expected to reverse at the reduced rate. As a result of the corporate tax rate decrease from the Tax Cuts and Jobs Act (TCIA), the deferred tax assets and valuation allowance have been reduced by approximately $3,383,000 at December 31, 2017. ASC 740, “Income Taxes” requires that a valuation allowance be established when it is “more likely than not” that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of December 31, 2017 and 2016. For the years ended December 31, 2017 and December 31, 2016, the change in valuation allowance was a decrease of $1,837,000 and an increase of $1,361,000, respectively. The Company recognizes interest and penalties relating to unrecognized tax benefits on the income tax expense line in the statement of operations. There are no tax penalties and interest on the statement of operations as of December 31, 2017, 2016 and 2015. The Company operates in multiple tax jurisdictions and, in the normal course of business, its tax returns are subject to examination by various taxing authorities. Such examinations may result in future assessments by these taxing authorities. The Company is subject to examination by U.S. tax authorities beginning with the year ended December 31, 2014. No accrued interest and penalties are included on the related tax liability accrual on the balance sheet. There are no accrued interest and penalties at December 31, 2017 and December 31, 2016.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 21 — Subsequent Events Common Stock Issue Subsequent to December 31, 2017, the Company issued: 32,540 shares of common stock issued upon vesting of restricted stock awards with an aggregate fair value of $3.85 at the time of vesting. 27,581 shares of common stock issued upon vesting of restricted stock units (RSUs) with an aggregate fair value of $3.65 at the time of vesting. 1,193,556 shares of common stock to warrant holders upon the exercise of 949,111 warrants, which had a weighted average strike price of $2.95.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On December 20, 2016, the Company filed with the State of Delaware the Seventh Amended and Restated Certificate of Incorporation for a one-for
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at December 31, 2017. As of December 31, 2016, the Company had no cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for doubtful accounts based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. No allowance for doubtful accounts was necessary at December 31, 2017 and 2016.
Inventories	Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is determined using a specific identification method. The Company reduces the carrying value of inventory for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors. In addition, the carrying value of consigned inventories is reduced by the value of MyPro devices that will not be sold based on historical experience.
Restricted Cash	Restricted Cash Restricted cash consisted of cash deposited with a financial institution as collateral for Company credit cards for sales personnel.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are comprised of direct incremental legal, accounting and financial advisor fees related relating to capital raising efforts. Deferred offering costs are offset against proceeds of an offering. In the event a capital raising effort is terminated, deferred offering costs are expensed.
Equipment	Equipment Equipment is stated at historical cost, net of accumulated depreciation and is depreciated using the straight-line method over the estimated useful lives of the related assets, generally three years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.
Impairment of Long-Lived Assets	Impairment of Long Lived Assets The Company assesses the recoverability of its long-lived assets, including equipment when there are indications that the assets might be impaired. When evaluating assets for potential impairment, the Company compares the carrying value of the asset to its estimated undiscounted future cash flows. If an asset’s carrying value exceeds such estimated cash flows (undiscounted and with interest charges), the Company records an impairment charge for the difference. Based on its assessments, the Company did not record any impairment charges for the years ended December 31, 2017 and 2016.
Demonstration and Test Units	Demonstration and Test Units Demonstration units represent units provided to customers by the Company for marketing and patient evaluation purposes. These units are manufactured by the Company and are recorded at cost in the statements of operations as part of selling, marketing and general administrative expense. During the years ended December 31, 2017 and 2016, respectively, the Company charged to operations approximately $26,900 and $22,900, respectively, of these units. Test units represent units provided to research and development staff to use in their development process and to end users who are given free units to act as testers so that research and development staff can evaluate and understand their use by patients. A primary objective of these units is to determine when and under what conditions they fail, at which time they are analyzed for cause of failure and then scrapped. These units are recorded at cost in the statements of operations as part of research and development expense. During the year ended December 31, 2017 and 2016 the Company charged to operations approximately $29,200 and $48,000, respectively, of these units. Accounts Payable and Other Accrued Expenses: 2017 2016 Trade payables $ 264,890 $ 311,085 Accrued compensation and benefits 642,425 221,630 Accrued directors fees 100,000 — Accrued offering costs — 77,326 Other 269,921 103,969 $ 1,277,236 $ 714,010
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity under U.S. GAAP when determining the classification and measurement of its convertible preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as permanent equity. The Company’s preferred shares at December 31, 2016 featured certain redemption rights that were considered by the Company to be outside the Company’s control. Accordingly, the Series A-1 B-1 As of the issuance date, the carrying amount of the Preferred Stock was less than the redemption value. If the Preferred Stock is redeemable at the investor’s option, the carrying value would be increased by periodic accretions so that the carrying value would equal the redemption amount at the earliest redemption date. Such accretion would be recorded as a preferred stock dividend.
Derivative Liabilities	Derivative Liabilities The Company accounts for warrants determined to be derivative financial instruments by recording the warrants as a liability at fair value and marks-to-market
Revenue Recognition	Revenue Recognition The Company derives revenue primarily from the sale of its products to orthotics and prosthetics practices, as well as Veteran Administration and other hospitals and, beginning in 2017, through a distribution agreement with Ottobock. The Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable, and collectability is deemed probable. In certain cases, the Company ships the MyPro device to O&P practices pending reimbursement from third party payors. As a result of this arrangement, elements of the revenue recognition criteria have not been met upon shipment of the MyoPro. The Company recognizes revenue when payment has been received, as all of the revenue recognition criteria has been met. During 2017, effective with its introduction of its extended product line, the Company provides a standard three-year warranty. This revenue is recognized ratably over the warranty period. The Company allocates revenue to the warranty element of a sale based upon its fair value as determined by referencing the historical selling price of it in similar transactions. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies. As such, we have delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The Company receives federally-funded grants that require the Company to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. The Company’s grant revenue is recognized when persuasive evidence of the arrangement exists, the service has been provided and adherence to specific parameters of the awarded grant have been met, the amount is fixed and determinable and collection is reasonable assured. The Company recognized approximately $118,100, $20,800 and $131,900, respectively, of grant income in 2017, 2016 and 2015, respectively. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Cost of revenue includes reimbursable costs of approximately $11,600 and $10,100 in 2017 and 2016, respectively. Amounts received in advance are deferred.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs paid by customers are netted against the related shipping costs we incur. The net cost is recorded in cost of sales. Historically, such costs have not been material.
Income Taxes	Income Taxes The Company accounts for income taxes under Accounting Standards Codification ASC 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the financial statement in the period in which the law is enacted. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows. The Company files income tax returns in federal and state jurisdictions and is no longer subject to examinations by tax authorities for years prior to 2014. Currently, there are no income tax audits in process.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock awards to employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Options and warrants granted to consultants and other non-employees Stock-based compensation expense of approximately $279,500 and $94,100 was recorded in selling, general and administrative expense in 2017 and 2016, respectively.
Net Loss per Share	Net Loss per Share Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the years ended December 31, 2017 and 2016, respectively, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potentially common shares issuable at December 31, 2017 and 2016 consist of: 2017 2016 Options 369,004 246,344 Warrants 6,277,443 10,781 Series B-1 — 1,662,104 Series A-1 — 960,083 Total 6,646,447 2,879,312
Advertising	Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $31,000 and 41,600 in 2017 and 2016, respectively.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs primarily consist of salaries and benefits, facility and overhead costs, and outsourced research activities.
Reclassification	Reclassification Certain amounts in the 2016 financial statements of operations have been reclassified to conform to the 2017 presentation. These reclassifications had no impact on previously reported net loss.
Subsequent Events	Subsequent Events The Company evaluates events and/or transactions occurring after the balance sheet date and before the issue date of the financial statements to determine if any of those events and/or transactions require adjustment to or disclosure in the financial statements.
Revision of Financial Statements	Revision of Financial Statements During the preparation of its Offering Circular Supplement for the quarterly period ended March 31, 2017, the Company determined it had improperly classified its Notes Payable, MLSC and certain related accrued interest as long-term liabilities, which resulted in an understatement of current liabilities as of December 31, 2016. The Company assessed the materiality of the misstatement in accordance with Staff Accounting Bulletin No. 99, “Materiality” and No. 108, “Quantifying Misstatements”, and concluded that these classification errors were not qualitatively material and there was no impact on the Company’s condensed statements of operations, cash flows, changes in redeemable and convertible preferred stock and stockholders’ equity (deficiency) and net loss per share for the years then ended, nor on the Company’s stockholders’ equity (deficiency). As such, the correction of the error is reflected in the December 31, 2016 balance sheet. Disclosure of the revised amounts will also be reflected in future filings containing the applicable periods. The effect of this revision on the line items within the Company’s balance sheet as of December 31, 2016 was as follows: December 31, 2016 As previously Adjustment As revised Total current liabilities $ 1,807,311 $ 1,193,984 $ 3,001,295 Non-current 4,709,156 (1,193,984 ) 3,515,172 Total liabilities $ 6,516,467 $ — $ 6,516,467
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Related Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, 2014-09”). 2014-09 2014-09 2014-09 No. 2015-14, No. 2014-09 ASU 2014-09 2016-08 In March 2016, the FASB issued ASU No. 2016-08, ASU No. 2014-09 — 2014-09, ASU 2016-08 On May 2016, the FASB issued ASU No. 2016-12, (“ASU 2016-12”). 2016-12 2014-09. 2014-09, In September 2017, the FASB issued ASU No. 2017-13, The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies. As such, the Company has delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. Other Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, 2016-02”). 2016-02 ASU 2016-02 ASU 2016-02 2016-02 In March 2016, the FASB issued ASU No. 2016-09, In August 2016, the FASB issued ASU 2016-15, 2016-15 In November 2016, the FASB issued ASU 2016-18, 2016-18 In May 2017, the FASB issued ASU No. 2017-09, 2017-09 In July 2017, the FASB issued ASU No. 2017-11, No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11 No. 2017-11. 2017-11 Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Accounts Payable and Other Accrued Expenses	Accounts Payable and Other Accrued Expenses: 2017 2016 Trade payables $ 264,890 $ 311,085 Accrued compensation and benefits 642,425 221,630 Accrued directors fees 100,000 — Accrued offering costs — 77,326 Other 269,921 103,969 $ 1,277,236 $ 714,010
Summary of Potentially Common Shares Issuable	Potentially common shares issuable at December 31, 2017 and 2016 consist of: 2017 2016 Options 369,004 246,344 Warrants 6,277,443 10,781 Series B-1 — 1,662,104 Series A-1 — 960,083 Total 6,646,447 2,879,312
Schedule of Effect of Revision on Balance Sheet	The effect of this revision on the line items within the Company’s balance sheet as of December 31, 2016 was as follows: December 31, 2016 As previously Adjustment As revised Total current liabilities $ 1,807,311 $ 1,193,984 $ 3,001,295 Non-current 4,709,156 (1,193,984 ) 3,515,172 Total liabilities $ 6,516,467 $ — $ 6,516,467

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following at December 31: 2017 2016 Finished goods $ 122,000 $ 81,223 Consigned inventory 97,980 — Parts and components 23,530 1,213 243,510 82,435 Less: excess and obsolete inventory reserves (23,739 ) — Less: consigned inventory reserves (18,616 ) — Inventories, net $ 201,155 $ 82,435

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Equipment	Equipment consists of the following at December 31: 2017 2016 Computer equipment $ 32,257 $ 19,258 Sales demonstration units 54,003 — R&D tools and molds 22,650 22,650 108,910 41,908 Less: accumulated depreciation (31,760 ) (20,345 ) Equipment, net $ 77,150 $ 21,563

Fair Value of Financial Instr34

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis	Cash equivalents and derivative liabilities (see Note 17) measured at fair value on a recurring basis at December 31, 2017 were as follows: In Active Markets Significant Other Significant December 31, Cash equivalents $ 10,459,435 — — $ 10,459,435 Common stock warrant liabilities — — $ 39,930 $ 39,930
Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the year ended December 31, 2017 and 2016: Common stock Balance – January 1, 2016 $ 2,239 Change in fair value of derivative liabilities (2,329 ) Balance – December 31, 2016 — Fair value of common stock warrant issued 156,725 Change in fair value of derivative liabilities (116,795 ) Balance – December 31, 2017 $ 39,930
Schedule of Fair Value Assumptions	As of December 31, 2016 the significant assumptions used in this model was as follows: 2016 Market value 9.0 million Volatility 81% Time to liquidity 2.0 years Risk free rate 0.58% Discount for lack of marketability 25%
Significant Unobservable Inputs (Level 3) [Member]
Schedule of Fair Value Assumptions	Assumptions utilized in the valuation of Level 3 liabilities at December 31, were as follows: 2017 2016 Risk-free interest rate 2.20% — Expected life 4.44 years — Expected volatility of underlying stock 63% — Expected dividend yield — —

Fair Value of Common Stock De35

Fair Value of Common Stock December 31, 2016 (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Fair Value of Outstanding Securities	As of December 31, 2016, the fair value of the Company’s outstanding securities was as follows: 2016 Common Stock $ 1.04 Series B-1 $ 4.06 Series A-1 $ 1.25

Redeemable Preferred Stock (Tab

Redeemable Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Authorized, Issued and Outstanding Preferred Stock	The following table below summarizes the authorized, issued and outstanding Preferred Stock as of December 31, 2016: Shares Shares Par Value Cumulative Dividend Liquidation Series B-1 1,862,500 1,662,104 $ 0.0001 $ 1,495,127 $ 0.90 $ 9,701,313 Series A-1 1,594,958 960,083 $ 0.0001 $ — $ — $ 4,740,066

Stock Award Plans and Stock-b37

Stock Award Plans and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	Stock option activity under the Stock Option Plans during the years ended December 31, 2017 and 2016 is as follows: Shares Weighted Weighted Intrinsic Balance at January 1, 2016 272,494 $ 0.1088 6.95 $ 207,146 Granted 101,661 $ 0.9987 Forfeited or cancelled (3,352 ) $ 0.5125 Exercised (124,459 ) $ 0.0259 Balance at December 31, 2016 246,344 $ 0.5133 7.10 $ 132,121 Granted 210,600 $ 2.6568 Forfeited or cancelled (7,855 ) $ 0.9717 Exercised (80,085 ) $ 0.3366 Balance at December 31, 2017 369,004 $ 1.7652 8.65 $ 732,399 Options exercisable at December 31, 2016 140,724 $ 0.3464 5.68 $ 99,879 Options exercisable at December 31, 2017 141,847 $ 0.6906 7.39 $ 433,960
Schedule of Grant Date Fair Value	The assumptions underlying the calculation of grant date fair value are as follows: 2017 2016 Volatility 62.71%-80.00% 81.00% Risk-free interest rate 0.58%-2.29% 0.58% Weighted-average expected option term (in years) 5.75-6.25 5.75-6.25 Dividend yield 0% 0%
Summary of Restricted Stock Activity	Restricted stock activity is summarized below: Number of Shares Weighted average Weighted average Outstanding as of January 1, 2017 — $ — — Awarded 46,500 6.75 Vested (312 ) 6.75 Canceled (2,000 ) 6.75 Outstanding as of December 31, 2017 44,188 $ 6.75 6.75
Schedule of Stock-based Compensation Expense	The Company recognized stock-based compensation expense related primarily to the issuance of stock option awards to employees and non-employees 2017 2016 Research and development $ 12,382 $ — Selling, general and administrative 267,126 94,094 Total $ 279,508 $ 94,094

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Summary of Common Stock Warrants Activity	The following table presents the Company’s common stock warrant activity for the years ended December 31, 2017 and 2016: Warrants Weighted Average Outstanding Exercisable Outstanding Exercisable Balance, Jan 1, 2016 8,228 8,228 $ 6.47 $ 6.47 Issued — — — — Exercised — — — — Balance, Dec 31, 2016 8,228 8,228 6.47 6.47 Issued 6,304,015 6,220,515 3.84 3.85 Exercised (34,800 ) (34,800 ) 2.95 2.95 Balance, Dec 31, 2017 6,277,443 6,193,943 $ 3.85 $ 3.86

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Amounts Due under Agreement	The future minimum amounts due under this agreement for the next five years and thereafter are as follows: 2018 $ 25,000 2019 25,000 2020 25,000 2021 25,000 2022 through expiration of the patents 50,000
Summary of Changes in Warranty Liability	Changes in warranty liability were as follows: 2017 2016 Accrual provided for warranties issued during the period Accrued warranty liability, beginning of year $ 63,147 $ 2,994 Accrual provided for warranties issued during the period 14,867 67,382 Adjustments to prior accruals 570 (3,773 ) Actual warranty expenditures (27,859 ) (3,456 ) Accrued warranty liability, end of year $ 50,725 $ 63,147

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Summary of Tax Provision (Benefit)	The income tax provision (benefit) for the years ended December 31, 2017 and 2016 consist of the following: 12/31/17 12/31/16 U.S. federal Current $ — $ — Deferred (534,000 ) (1,184,000 ) State and local Current — — Deferred ( ) (177,000 ) (1,072,000 ) (1,361,000 ) Deferred tax expense related to tax law change 2,909,000 — Change in valuation allowance (1,837,00 0 ) 1,361,000 Income $ — $ —
Summary of Reconciliation between U.S. Statutory Federal Income Tax Rate and Effective Rate	The reconciliation between the U.S statutory federal income tax rate and the Company’s effective rate for the years ended December 31, 2017 and 2016 is as follows: 12/31/17 12/31/16 U.S. federal statutory rate 34.00 % 34.00 % State income taxes, net of federal benefit 4.67 % 5.45 % Federal rate change, deferred items -23.03 % 0.00 % State rate change and other 0.89 % -0.54 % Non-deductible -17.67 % — Federal NOLs to expire unutilized due to sec 382 limitation -14.02 % -0.00 % Other permanent items -0.03 % -0.29 % Change in valuation allowance 15.19 % —38.62 % Effective rate 0.00 % 0.00 %
Summary of Deferred Tax Assets	As of December 31, 2017, and 2016, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: 12/31/17 12/31/16 Net operating loss carryover $ 5,925,000 $ 7,876,000 Tax credits 190,000 189,000 Stock-based compensation 53,000 19,000 Other 219,000 140,000 Total deferred tax asset 6,387,000 8,224,000 Less: valuation allowance ( ) (8,224,000 ) Deferred tax asset, net of valuation allowance $ — $ —

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)		Dec. 06, 2017	Dec. 04, 2017	Nov. 13, 2017	Jun. 09, 2017	May 23, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 20, 2016
Organization Consolidation and Presentation of Financial Statements [Line Items]
Initial public offering raising amount	[1]						$ 4,368,315
Common stock warrants, exercise price per share					$ 6.47
Aggregate proceeds offering expenses							$ 2,922,885
Combined aggregate gross proceeds raised				$ 2,000,000	$ 7,916,620	$ 10,000,000
Authorized issue of shares					125,000,000
Common stock, shares authorized					100,000,000		100,000,000	100,000,000	5,600,000
Common stock, par value					$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized					25,000,000		25,000,000		4,100,000
Preferred stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses					$ 1,061,157
Sale of stock					665,498
IPO [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Initial public offering raising amount					$ 4,991,235
Other offering expenses					$ 1,061,157
Sale of stock					665,498
Sale of common stock price per share					$ 7.50
IPO [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Stock issued during period							665,498
Private Placement [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses					$ 2,500
Sale of stock					557,216
Sale of common stock price per share					$ 5.25
Share unit, description							Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
Common stock warrants, exercise price per share					$ 7.50
Warrant expiration period					3 years
Aggregate proceeds offering expenses					$ 2,925,385
FPO [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Warrants to purchase common stock			4,175,000
Warrant expiration date			Dec. 4, 2022
FPO [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Sale of common stock price per share			$ 2.40
Common stock warrants, exercise price per share			$ 2.95
Stock issued during period			4,175,000
FPO [Member] | Common Stock and Warrants [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Sale of common stock price per share		$ 2.40
Stock issued during period		626,250
Over-allotment Option [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses		$ 1,115,000	$ 1,115,000
Stock issued during period		4,801,250	4,801,250
Warrants to purchase common stock		4,801,250	4,801,250
Proceeds from sale of common stock		$ 11,523,000	$ 11,523,000
Over-allotment Option [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Stock issued during period							4,801,250
[1]	IPO gross proceeds of $4,991,236 are reduced by $622,921 of IPO offering costs that were incurred in 2017. Another $438,237 of IPO deferred offering costs were paid for in 2016.

Going Concern and Management'42

Going Concern and Management's Plan - Additional Information (Detail) - USD ($)	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Going Concern and Management's Liquidity Plan [Line Items]
Net loss		$ (12,097,479)	$ (3,617,022)
Accumulated deficit		(34,972,787)	(22,875,308)
Cash used in operating activities		$ (6,153,419)	$ (3,202,670)
Subsequent Event [Member]
Going Concern and Management's Liquidity Plan [Line Items]
Common stock issued to warrant holders	1,193,556
Number of warrant exercised	1,193,556
Common stock warrants, exercise price	$ 3,520,990

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Additional Information (Detail)	Dec. 20, 2016	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split, description		One-for sixteen
Reverse stock split conversion ratio	0.0625
Cash equivalents			$ 0
Allowance for doubtful accounts		$ 0	0
Equipment estimated useful lives		3 years
Impairment charges		$ 0	0
Standard warranty period		Three-year
Reimbursable costs		$ 11,600	10,100
Measurement of tax benefit, minimum likelihood of the largest amount being realized upon ultimate resolution		50.00%
Stock-based compensation expense		$ 279,508	94,094
Advertising expense		31,000	41,600
Selling, General and Administrative Expenses [Member]
Summary Of Significant Accounting Policies [Line Items]
Demonstration units, expenses		26,900	22,900
Stock-based compensation expense		267,126	94,094
Research and Development Expense [Member]
Summary Of Significant Accounting Policies [Line Items]
Test units, expenses		29,200	48,000
Stock-based compensation expense		12,382
Grant Income [Member]
Summary Of Significant Accounting Policies [Line Items]
Grant income recognized		$ 118,100	$ 20,800	$ 131,900

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Summary of Accounts Payable and Other Accrued Expenses (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Trade payables	$ 264,890	$ 311,085
Accrued compensation and benefits	642,425	221,630
Accrued directors fees	100,000
Accrued offering costs		77,326
Other	269,921	103,969
Total	$ 1,277,236	$ 714,010

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Summary of Potentially Common Shares Issuable (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,646,447	2,879,312
Series B-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		1,662,104
Series A-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		960,083
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	369,004	246,344
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,277,443	10,781

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Schedule of Effect of Revision on Balance Sheet (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Condensed Balance Sheet Statements, Captions [Line Items]
Total current liabilities	$ 1,485,172	$ 3,001,295
Non-current liabilities		3,515,172
Total liabilities	$ 1,529,214	6,516,467
As previously reported [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Total current liabilities		1,807,311
Non-current liabilities		4,709,156
Total liabilities		6,516,467
Adjustment [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Total current liabilities		1,193,984
Non-current liabilities		$ (1,193,984)

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 122,000	$ 81,223
Consigned inventory	97,980
Parts and components	23,530	1,213
Total cost	243,510	82,435
Less: excess and obsolete inventory reserves	(23,739)
Less: consigned inventory reserves	(18,616)
Inventories, net	$ 201,155	$ 82,435

Inventories - Additional Inform

Inventories - Additional Information (Detail)	Dec. 31, 2017USD ($)
Inventory Disclosure [Abstract]
Excess and obsolete inventory reserves	$ 23,739

Equipment - Schedule of Equipme

Equipment - Schedule of Equipment (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 108,910	$ 41,908
Less: accumulated depreciation	(31,760)	(20,345)
Equipment, net	77,150	21,563
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	32,257	19,258
Sales Demonstration Units [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	54,003
Research And Development Tools And Molds [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 22,650	$ 22,650

Revolving Line of Credit - Addi

Revolving Line of Credit - Additional Information (Detail) - USD ($)	Dec. 20, 2017	Dec. 31, 2017	Jun. 08, 2017
Line of Credit Facility [Line Items]
Proceeds from issuance of common stock		$ 10,407,706
Revolving Credit Facility [Member] | Chief Executive Officer and Director Agreement [Member]
Line of Credit Facility [Line Items]
Revolving line of credit			$ 1,000,000
Revolving line of credit, description		The line of credit will bear an interest rate of 10% of per annum and will terminate upon the earlier of (i) December 31, 2018; and (ii) the Company entering into a debt or loan facility with a bank or non-bank lender in the aggregate amount of not less than the greater of (A) $500,000 and (B) the then outstanding principal and interest under the facility.
Revolving Credit Facility [Member] | Over-allotment Option [Member]
Line of Credit Facility [Line Items]
Proceeds from issuance of common stock	$ 11,500,000

Notes Payable, MLSC - Additiona

Notes Payable, MLSC - Additional Information (Detail) - USD ($)

Dec. 13, 2017

Nov. 13, 2017

Jun. 09, 2017

Jun. 06, 2017

May 23, 2017

May 22, 2017

May 18, 2016

Dec. 31, 2017

Dec. 31, 2016

Mar. 31, 2017

Sep. 30, 2016

Dec. 31, 2015

Debt Instrument [Line Items]

Promissory note's maturity date

Jun. 8, 2019

Jun. 8, 2017

Proceeds from from equity financing

$ 2,000,000

$ 7,916,620

$ 10,000,000

Promissory notes due completion

30 days

Warrants outstanding purchase of common stock

3,591

6,277,443

8,228

8,228

Warrants exercisable price per share

$ 6.47

Repayment all outstanding principal and accrued but unpaid interest

$ 1,081,135

Massachusetts Life Sciences Center [Member]

Debt Instrument [Line Items]

Maximum number of shares of stock to be acquired under warrants

8,228

Numerator amount used in calculation of warrants exercise price for common stock

$ 2,500,000

Warrants exercisable price per share

$ 6.47

Repayment all outstanding principal and accrued but unpaid interest

$ 874,600

Promissory Notes [Member] | Massachusetts Life Sciences Center [Member]

Debt Instrument [Line Items]

Promissory notes

$ 750,000

Interest rate

10.00%

Promissory note principal and accrued interest, description

The principal and accrued interest is due and payable upon the earlier of (i) June 7, 2016, (ii) the closing of a Qualified Financing in a single transaction or series of transactions in any 12 month period yielding net proceeds of at least $5,000,000 or a qualified sale, as defined in the promissory notes, or (iii) the occurrence of a default, as defined in the promissory notes.

Warrants exercisable amount

$ 30,000

Percentage value used in calculation of proceeds from exercise of warrants

4.00%

Warrants life

10 years

Maximum number of shares of stock to be acquired under warrants

4,637

Promissory notes proceeds, description

Company completes an equity financing in any twelve-month period raising an aggregate of $10 million in gross proceeds.

Proceeds from from equity financing

$ 10,000,000

Promissory notes due completion

30 days

Convertible Promissory Notes 2016 [Member]

Debt Instrument [Line Items]

Interest rate

8.00%

8.00%

Promissory note's maturity date

Dec. 31, 2018

Convertible Promissory Notes 2016 [Member] | Massachusetts Life Sciences Center [Member]

Debt Instrument [Line Items]

Warrants outstanding purchase of common stock

4,637

Warrants exercisable price per share

$ 6.47

Promissory Note Restructuring on May 18, 2016 [Member] | Promissory Notes [Member] | Massachusetts Life Sciences Center [Member]

Debt Instrument [Line Items]

Promissory notes

$ 1,194,000

Interest rate

10.00%

Promissory note principal and accrued interest, description

The note bears interest at 10% per annum with accrued interest payable quarterly which began on September 30, 2016, and is secured by substantially all the Company's assets.

Promissory note's maturity date, description

On May 18, 2016, the Company restructured its promissory note with MLSC, extending the maturity date to June 7, 2017.

Promissory note's maturity date

Jun. 7, 2017

Gain (loss) recognized with modification of note

$ 0

Promissory Note Restructuring on June 6, 2017 [Member] | Promissory Notes [Member] | Massachusetts Life Sciences Center [Member]

Debt Instrument [Line Items]

Promissory notes

$ 1,216,000

Promissory note principal and accrued interest, description

The note bears interest was reduced to 7% per annum with approximately $54,000 in interest payable monthly beginning on June 7, 2019 with the principal and any remaining unpaid accrued interest due the earlier of June 7, 2019, or Company completes an equity financing in any twelve-month period raising an aggregate of $10 million in gross proceeds (a “Qualified Financing”), excluding the conversion into common stock in an initial public offering of any convertible notes outstanding on the date of this amendment.

Promissory note's maturity date, description

On June 6, 2017, the Company restructured its promissory note with MLSC, extending the maturity date to June 7, 2017.

Promissory note's maturity date

Jun. 7, 2017

Gain (loss) recognized with modification of note

$ 0

Promissory note bears reduced interest rate

7.00%

Monthly interest payable

$ 54,000

Notes Payable, Shareholder - Ad

Notes Payable, Shareholder - Additional Information (Detail) - USD ($)	Nov. 13, 2017	Jun. 09, 2017	May 23, 2017	May 22, 2017	Sep. 01, 2015	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Maturity date			Jun. 8, 2019	Jun. 8, 2017
Proceeds from exercise of warrants							$ 102,660
Proceeds from equity financing	$ 2,000,000	$ 7,916,620	$ 10,000,000
Promissory notes due completion			30 days
Percentage of common stock price per share	80.00%		80.00%
Aggregate warrant shares		3,591				6,277,443	6,277,443	8,228	8,228
Exercise price of warrants		$ 6.47
Period before which company elects to repay notes in shares of equity following financing by company of equity or equity linked securities	90 days
Repayment of outstanding principal and accrued but unpaid interest under notes	$ 1,081,135
Shares issued for repayment of outstanding principal and accrued but unpaid interest under notes	$ 86,004
Share price	$ 6.29
Percentage of price per share	80.00%
Gain (Loss) on extinguishment debt							$ (135,244)
Maximum [Member]
Short-term Debt [Line Items]
Percentage of repay promissory notes outstanding principal	50.00%		50.00%
Deferred Gain (Loss) on Early Extinguishment of Debt [Member]
Short-term Debt [Line Items]
Gain (Loss) on extinguishment debt						$ (135,244)
80% of Price per Share [Member]
Short-term Debt [Line Items]
Shares issued for repayment of outstanding principal and accrued but unpaid interest under notes	$ 107,505
Share price	$ 5.03
Shareholder [Member]
Short-term Debt [Line Items]
Proceeds from exercise of warrants							$ 23,232
Percentage value used in calculation of proceeds from exercise of warrants							4.00%
Warrants life							10 years
Numerator amount used in calculation of warrants exercise price for common stock							$ 2,500,000
Shareholder [Member] | Maximum [Member]
Short-term Debt [Line Items]
Maximum number of shares of stock to be acquired under warrants						4,706	4,706
Shareholder [Member] | Promissory Notes [Member]
Short-term Debt [Line Items]
Promissory notes						$ 580,800	$ 580,800
Interest rate						10.00%	10.00%
Maturity date							May 25, 2016
Accrued and unpaid interest					$ 295,700
Principal amount					876,500
Required monthly payments of principal and interest					44,500
Gain or loss with modification of note					$ 0

Convertible Promissory Notes 53

Convertible Promissory Notes 2016 - Additional Information (Detail) - USD ($)	Nov. 13, 2017	Jun. 09, 2017	Jun. 05, 2017	May 23, 2017	May 22, 2017	Oct. 03, 2016	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 12, 2016
Short-term Debt [Line Items]
Maturity date				Jun. 8, 2019	Jun. 8, 2017
Proceeds from convertible promissory note									$ 1,770,000	$ 2,956,218
Percentage of price per share	80.00%
Convertible promissory notes aggregate principal balance									$ 12,946,252
Warrants outstanding purchase of common stock		557,216
Warrants exercisable price per share		$ 7.50
Convertible Promissory Notes 2016 [Member]
Short-term Debt [Line Items]
Convertible promissory notes aggregate principal balance										$ 2,372,000		$ 1,000,000
Promissory notes interest rate								8.00%		8.00%
Maturity date										Dec. 31, 2018
Proceeds from convertible promissory note			$ 5,000,000							$ 5,000,000
Description of convertible promissory note									The number of shares of equity securities of the Company to be issued upon such conversion shall be equal to the quotient obtained by dividing the entire principal amount plus accrued interest by the lower of (i) a price per share equal to $35,000,000 divided by the aggregate number of shares of capital stock outstanding on a fully diluted basis immediately prior to the initial closing of the Qualified Financing
Numerator amount used in calculation of price per share										$ 35,000,000
Percentage of price per share										80.00%
Percentage of original principal amount of notes that will be paid to note holder as "Sale Premium"										25.00%
Percentage value of principal amount invested as numerator used in calculation of number of shares of stock to be acquired under warrants										100.00%
Deferred issuance costs										$ 20,800
Interest expense									$ 6,700	3,000
Convertible promissory notes, sales premium as a percentage of original principal amounts of notes						25.00%
Convertible promissory notes aggregate principal balance								$ 1,770,000
Convertible promissory noteholders exchanged								430,000		5,000,000
Accrued but unpaid interest, total		$ 5,467,389
Convertible common stock, shares		1,055,430
Weighted average price per share		$ 5.18
Warrants outstanding purchase of common stock							799,349
Warrants exercisable price per share							$ 6.47
Fair value of the warrants attributable							$ 1,628,006
Conversion option beneficial feature									3,825,320
Interest expense for issuance of warrants		$ 4,142,000
Deferred issuance costs									$ 20,800
Convertible Promissory Notes 2015 [Member]
Short-term Debt [Line Items]
Promissory notes interest rate									8.00%
Proceeds from convertible promissory note										5,000,000
Notes issued in exchange										630,000
Convertible promissory note									$ 1,030,000	3,002,000
Convertible promissory notes aggregate principal balance										$ 605,000	$ 425,000
Convertible promissory noteholders exchanged								$ 430,000
Warrants outstanding purchase of common stock									29,425
Warrants exercisable price per share									$ 5.25
Fair value of the warrants attributable									$ 457,456
Conversion option beneficial feature									1,003,867
Interest expense for issuance of warrants									$ 1,030,000

Convertible Promissory Notes 54

Convertible Promissory Notes 2015 - Additional Information (Detail) - USD ($)	Jun. 09, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Convertible promissory notes aggregate principal balance			$ 12,946,252
Proceeds from convertible promissory notes, net			$ 1,770,000	$ 2,956,218
Warrants outstanding purchase of common stock	557,216
Warrants exercisable price per share	$ 7.50
Convertible Promissory Notes 2015 [Member]
Short-term Debt [Line Items]
Convertible promissory notes aggregate principal balance				605,000	$ 425,000
Promissory notes interest rate			8.00%
Convertible promissory note			$ 1,030,000	3,002,000
Proceeds from convertible promissory notes, net				$ 5,000,000
Percentage per share value of lowest price per share			85.00%
Additional payment entitlement as percentage of convertible promissory notes held on maturity date			10.00%
Number of shares of stock to acquire as percentage determined by formula			15.00%
Prior notes cancelled in exchange for issue of new notes				400,000
Convertible promissory noteholders exchanged		$ 430,000
Warrants outstanding purchase of common stock			29,425
Warrants exercisable price per share			$ 5.25
Fair value of the warrants attributable			$ 457,456
Warrants acquired, description			The number of shares of stock to be acquired under the warrants is determined by a formula which amounts to 15% of the principal amount invested divided by the lowest price paid per share for the equity securities by the investors in the Equity Financing as defined.
Conversion option beneficial feature			$ 1,003,867
Interest expense for issuance of warrants			$ 1,030,000
Convertible Promissory Notes 2015 [Member] | Adjustment [Member]
Short-term Debt [Line Items]
Prior notes cancelled in exchange for issue of new notes				630,000

Fair Value of Financial Instr55

Fair Value of Financial Instruments - Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 10,459,435
Common stock warrant liabilities	39,930	$ 2,239
In Active Markets for Identical Assets or Liabilities (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	10,459,435
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common stock warrant liabilities	$ 39,930

Fair Value of Financial Instr56

Fair Value of Financial Instruments - Additional Information (Detail)	Dec. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Cash equivalents	$ 0

Fair Value of Financial Instr57

Fair Value of Financial Instruments - Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Beginning balance		$ 2,239
Fair value of common stock warrant issued	$ 156,725
Change in fair value of derivative liabilities	(116,795)	$ (2,329)
Ending balance	$ 39,930

Fair Value of Financial Instr58

Fair Value of Financial Instruments - Schedule of Assumptions Utilized in Valuation of Level 3 Liabilities (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Risk-free interest rate	2.20%	0.58%
Assumed time-to-liquidity	4 years 5 months 9 days	2 years
Expected volatility of underlying stock	63.00%	81.00%
Expected dividend yield	0.00%	0.00%

Fair Value of Common Stock De59

Fair Value of Common Stock December 31, 2016 - Summary of Significant Assumptions used in Option Pricing Model (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Market value		$ 9
Volatility	63.00%	81.00%
Time to liquidity	4 years 5 months 9 days	2 years
Risk free rate	2.20%	0.58%
Discount for lack of marketability		25.00%

Fair Value of Common Stock De60

Fair Value of Common Stock December 31, 2016 - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assumed time-to-liquidity	4 years 5 months 9 days	2 years
Volatility rate	63.00%	81.00%
Discount for lack of marketability		25.00%

Fair Value of Common Stock De61

Fair Value of Common Stock December 31, 2016 - Summary of Fair Value of Outstanding Securities (Detail) - $ / shares	Nov. 13, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common Stock	$ 6.29
Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common Stock		$ 1.04
Series A-1 Preferred Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Preferred Stock		1.25
Series B-1 Preferred Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Preferred Stock		$ 4.06

Common Stock - Additional Infor

Common Stock - Additional Information (Detail)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 06, 2017USD ($)$ / sharesshares	Dec. 04, 2017USD ($)$ / sharesshares	Nov. 13, 2017USD ($)$ / sharesshares	Jun. 09, 2017USD ($)$ / sharesshares	Dec. 20, 2016$ / sharesshares	Jun. 30, 2017USD ($)shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 03, 2017USD ($)shares	Dec. 31, 2016USD ($)$ / sharesshares
Class of Stock [Line Items]
Aggregate proceeds offering expenses | $								$ 2,922,885
Common stock warrants, exercise price per share | $ / shares					$ 6.47
Authorized issue of shares					125,000,000
Common stock, shares authorized	100,000,000				100,000,000	5,600,000		100,000,000		100,000,000
Common stock, par value | $ / shares	$ 0.0001				$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized	25,000,000				25,000,000	4,100,000		25,000,000
Preferred stock, par value | $ / shares	$ 0.0001				$ 0.0001	$ 0.0001		$ 0.0001
Repayment of outstanding principal and accrued interest | $				$ 1,081,135				$ 1,215,900
Common stock shares issued	11,139,667							11,139,667		1,124,888
Common stock issued for the exercise of common stock options, shares								80,085		124,459
Proceeds from exercise of stock options | $								$ 26,954		$ 2,873
Common stock issued for the exercise of warrants, shares								34,800
Common stock issued for the exercise of warrants | $								$ 102,660
Fair value of stock issued | $				$ 86,004
Common stock, shares outstanding	11,138,859							11,138,859		1,124,080
Reverse stock split, description								One-for sixteen
Reverse stock split conversion ratio						0.0625
Restricted Stock [Member]
Class of Stock [Line Items]
Common stock, shares outstanding										253,783
Provisions for lapsing forfeiture rights extended period										48 months
Unamortized stock compensation expense | $	$ 177,400							$ 177,400
Weighted-average remaining contractual term								3 years 7 months 17 days
Employee Stock Option [Member]
Class of Stock [Line Items]
Common stock subject to forfeiture										2,626
Unamortized stock compensation expense | $	$ 348,000							$ 348,000		$ 2,300
Weighted-average remaining contractual term	2 years 2 months 23 days									29 days
2004 Stock Option and Incentive Plan and 2014 Stock Option and Grant Plan [Member]
Class of Stock [Line Items]
Shares reserved for issuance upon the exercise of stock options										806,313
80% of Share Price on Repayment Date [Member]
Class of Stock [Line Items]
Common stock shares price per share | $ / shares				$ 5.03
Common stock shares issued				107,505
20% Share Price on Repayment Date [Member]
Class of Stock [Line Items]
Common stock shares price per share | $ / shares				$ 6.29
Common stock shares issued				86,004
Convertible Promissory Notes 2016 [Member]
Class of Stock [Line Items]
Accrued but unpaid interest, total | $					$ 5,467,389
Convertible common stock, shares					1,055,430
Weighted average price per share | $ / shares					$ 5.18
Private Placement [Member]
Class of Stock [Line Items]
Other offering expenses | $					$ 2,500
Sale of stock					557,216
Common stock shares price per share | $ / shares					$ 5.25
Aggregate proceeds offering expenses | $					$ 2,925,385
Warrant expiration period					3 years
Common stock warrants, exercise price per share | $ / shares					$ 7.50
Share unit, description								Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
FPO [Member]
Class of Stock [Line Items]
Warrants to purchase common stock			4,175,000
Warrant expiration date			Dec. 4, 2022
Over-allotment Option [Member]
Class of Stock [Line Items]
Other offering expenses | $		$ 1,115,000	$ 1,115,000
Stock issued during period		4,801,250	4,801,250
Warrants to purchase common stock		4,801,250	4,801,250
Proceeds from sale of common stock | $		$ 11,523,000	$ 11,523,000
Fair value of stock issued | $								$ 10,407,706
Common Stock [Member]
Class of Stock [Line Items]
Common stock raising | $					$ 4,991,235
Other offering expenses | $					$ 1,061,157
Sale of stock					665,498
Sale of stock price per share | $ / shares					$ 7.50
Convertible common stock, shares								1,055,430
Common stock issued for the exercise of common stock options, shares								80,085	80,085	124,456
Proceeds from exercise of stock options | $									$ 26,954	$ 2,873
Common stock issued for the exercise of warrants, shares								34,800
Common stock issued for the exercise of warrants | $								$ 3
Shares issued for services								4,000
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock, Shares								2,622,187		2,622,187
Common Stock [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock on a private placement , description								The Company also closed on a private placement pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
Common Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Shares issued for services							4,000
Fair value of stock issued | $							$ 30,000
Common Stock [Member] | FPO [Member]
Class of Stock [Line Items]
Common stock shares price per share | $ / shares			$ 2.40
Common stock warrants, exercise price per share | $ / shares			$ 2.95
Stock issued during period			4,175,000
Common Stock [Member] | Over-allotment Option [Member]
Class of Stock [Line Items]
Stock issued during period								4,801,250
Fair value of stock issued | $								$ 480
Common Stock and Warrants [Member] | FPO [Member]
Class of Stock [Line Items]
Common stock shares price per share | $ / shares		$ 2.40
Stock issued during period		626,250

Treasury Stock - Additional Inf

Treasury Stock - Additional Information (Detail) - shares	Dec. 31, 2017	Dec. 31, 2016
Treasury Stock, Shares [Abstract]
Treasury stock, common, shares	808	808

Redeemable Preferred Stock - Ad

Redeemable Preferred Stock - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Series B-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Common stock shares issued	1,662,104
Conversion of common stock, shares	1,662,104
Convertible preferred stock, shares issued	1,662,104
Convertible preferred stock, shares outstanding	1,662,104
Gross proceeds from conversion of preferred stock | $	$ 15,000,000
Accrued dividend rate per share | $ / shares	$ 0.3949568
Series A-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Common stock shares issued	960,083
Conversion of common stock, shares	960,083
Convertible preferred stock, shares issued	960,083
Convertible preferred stock, shares outstanding	960,083
Gross proceeds from conversion of preferred stock | $	$ 15,000,000

Redeemable Preferred Stock - Su

Redeemable Preferred Stock - Summary of Authorized, Issued and Outstanding Preferred Stock (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Series B-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	1,862,500
Shares Issued and Outstanding	1,662,104
Par Value per Share | $ / shares	$ 0.0001
Cumulative Dividends | $	$ 1,495,127
Dividend Arrearage Per Share | $ / shares	$ 0.90
Liquidation Preference Including Dividend Arrearage | $	$ 9,701,313
Series A-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	1,594,958
Shares Issued and Outstanding	960,083
Par Value per Share | $ / shares	$ 0.0001
Liquidation Preference Including Dividend Arrearage | $	$ 4,740,066

Stock Award Plans and Stock-b66

Stock Award Plans and Stock-based Compensation - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Aug. 15, 2017	Oct. 25, 2016	Sep. 30, 2014	Dec. 31, 2017	Dec. 31, 2016	Aug. 23, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit recognized					$ 0	$ 0
weighted-average grant date fair value per share					$ 1.62	$ 0.72
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted		46,500
Aggregate fair market value on the date of grant		$ 313,900
Compensation expense					$ 123,000
Unrecognized compensation cost	$ 177,400				$ 177,400
Weighted-average remaining contractual term					3 years 7 months 17 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 348,000				$ 348,000	$ 2,300
Weighted-average remaining contractual term	2 years 2 months 23 days					29 days
Maximum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Minimum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 months
2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional awards granted			0
Number of common shares reserved for issuance			562,500
Number of shares available for future grant	377,000				377,000
2014 Stock Option and Grant Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares reserved for issuance							899,549
2014 Stock Option and Grant Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
2014 Stock Option and Grant Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				10 years

Stock Award Plans and Stock-b67

Stock Award Plans and Stock-based Compensation - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares, Beginning balance	246,344	272,494
Shares, Granted	210,600	101,661
Shares, Forfeited or cancelled	(7,855)	(3,352)
Shares, Exercised	(80,085)	(124,459)
Shares, Ending balance	369,004	246,344	272,494
Weighted average exercise price, Beginning balance	$ 0.5133	$ 0.1088
Shares, Options exercisable	141,847	140,724
Weighted average exercise price, Granted	$ 2.6568	$ 0.9987
Weighted average exercise price, Forfeited or cancelled	0.9717	0.5125
Weighted average exercise price, Exercised	0.3366	0.0259
Weighted average exercise price, Ending balance	$ 1.7652	$ 0.5133	$ 0.1088
Intrinsic value, Beginning balance	$ 132,121	$ 207,146
Weighted average exercise price, Options exercisable	$ 0.6906	$ 0.3464
Intrinsic value, Ending balance	$ 732,399	$ 132,121	$ 207,146
Weighted average remaining life	8 years 7 months 24 days	7 years 1 month 6 days	6 years 11 months 12 days
Intrinsic value, Options exercisable	$ 433,960	$ 99,879
Weighted average remaining life, Options exercisable	7 years 4 months 20 days	5 years 8 months 5 days

Stock Award Plans and Stock-b68

Stock Award Plans and Stock-based Compensation - Schedule of Grant Date Fair Value (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Option Indexed to Issuer's Equity [Line Items]
Volatility		81.00%
Risk-free interest rate		0.58%
Dividend yield	0.00%	0.00%
Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Volatility	62.71%
Risk-free interest rate	0.58%
Weighted-average expected option term (in years)	5 years 9 months	5 years 9 months
Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Volatility	80.00%
Risk-free interest rate	2.29%
Weighted-average expected option term (in years)	6 years 2 months 30 days	6 years 2 months 30 days

Stock Award Plans and Stock-b69

Stock Award Plans and Stock-based Compensation - Summary of Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Awarded	6,304,015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Awarded	46,500
Number of shares, Vested	(312)
Number of shares, Canceled	(2,000)
Number of shares outstanding, ending balance	44,188
Weighted average grand fair value, Awarded	$ 6.75
Weighted average grand fair value, Vested	6.75
Weighted average grand fair value, Canceled	6.75
Weighted average grand fair value outstanding, ending balance	$ 6.75
Weighted average remaining contractual life	6 years 9 months	0 years

Stock Award Plans and Stock-b70

Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 279,508	$ 94,094
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	12,382
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 267,126	$ 94,094

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($)	Dec. 06, 2017	Dec. 04, 2017	Jun. 09, 2017	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Warrants outstanding purchase of common stock, Shares			557,216
Warrants exercisable price per share			$ 7.50
Warrants are fully vested, exercise price			$ 8.25
Fair value of the warrants derivative liability			$ 156,725	$ 39,930
Common stock warrants, exercise price per share			$ 6.47
Warrants issued, description				The Company issued warrants that expire in 2021 for the purchase of an aggregate of 8,228 shares of stock at an exercise price of $6.47 per share.
Weighted average remaining contractual life of warrants outstanding and exercisable				7 years 4 months 20 days	5 years 8 months 5 days
Massachusetts Life Sciences Center [Member]
Class of Warrant or Right [Line Items]
Common stock warrants, exercise price per share				$ 6.47
Warrant expiration date				Dec. 31, 2021
Warrants to purchase common stock				8,228
Warrants [Member]
Class of Warrant or Right [Line Items]
Weighted average remaining contractual life of warrants outstanding and exercisable				4 years 4 months 13 days
IPO Selling Agent [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants issued			33,275
FPO [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants issued		4,175,000
Warrant expiration date		Dec. 4, 2022
Warrants to purchase common stock		4,175,000
FPO [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrants, exercise price per share		$ 2.95
Stock issued during period		4,175,000
FPO [Member] | Common Stock and Warrants [Member]
Class of Warrant or Right [Line Items]
Stock issued during period	626,250
Over-allotment Option [Member]
Class of Warrant or Right [Line Items]
Stock issued during period	4,801,250	4,801,250
Warrants to purchase common stock	4,801,250	4,801,250
Over-allotment Option [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock issued during period				4,801,250
Underwriters Follow on Public Offering [Member]
Class of Warrant or Right [Line Items]
Warrants years of life		3 years
Purchase of warrants issued		83,500
Warrants are fully vested, exercise price		$ 2.40
2016 Convertible Promissory Notes [Member] | IPO [Member]
Class of Warrant or Right [Line Items]
Warrants years of life			3 years
Purchase of warrants issued				799,349
Convertible Promissory Notes 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding purchase of common stock, Shares				29,425
Warrants exercisable price per share				$ 5.25
Convertible Promissory Notes 2015 [Member] | IPO [Member]
Class of Warrant or Right [Line Items]
Warrants years of life			5 years
Purchase of warrants issued				29,425

Warrants - Summary of Common St

Warrants - Summary of Common Stock Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Warrants outstanding, beginning balance	8,228	8,228
Warrants outstanding, issued	6,304,015
Warrants outstanding, exercised	(34,800)
Warrants outstanding, ending balance	6,277,443	8,228
Warrants exercisable, beginning balance	8,228	8,228
Warrants exercisable, issued	6,220,515
Warrants exercisable, exercised	(34,800)
Warrants exercisable, beginning balance	6,193,943	8,228
Weighted average exercise price outstanding, beginning balance	$ 6.47	$ 6.47
Weighted average exercise price outstanding, issued	3.84
Weighted average exercise price outstanding, exercised	2.95
Weighted average exercise price outstanding, ending balance	3.85	6.47
Weighted average exercise price exercisable, beginning balance	6.47	6.47
Weighted average exercise price exercisable, issued	3.85	0
Weighted average exercise price exercisable, exercised	2.95	0
Weighted average exercise price exercisable, ending balance	$ 3.86	$ 6.47

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 04, 2017	Jun. 09, 2017	Dec. 31, 2017	Dec. 31, 2016	Nov. 13, 2017
Related Party Transaction [Line Items]
Revenue recognized from related party			$ 53,500	$ 49,100
Accounts receivable			77,600	24,500
Charges for services			356,400	156,900
Accounts payable and accrued expenses			$ 65,800	6,600
Share price					$ 6.29
Common stock warrants, exercise price per share		$ 6.47
Private Placement [Member]
Related Party Transaction [Line Items]
Common stock warrants, exercise price per share		$ 7.50
Director [Member]
Related Party Transaction [Line Items]
Purchase of subordinated convertible promissory notes				$ 1,080,000
Directors And Officers [Member]
Related Party Transaction [Line Items]
Stock issued during period	285,000	14,000
Share price	$ 2.40	$ 7.50
Warrants to purchase common stock	285,000
Common stock warrants, exercise price per share	$ 2.95
Directors And Officers [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Stock issued during period		125,238
Share price		$ 5.25
Warrants to purchase common stock		125,238
Common stock warrants, exercise price per share		$ 7.50
Directors And Officers [Member] | Series B-1 Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Purchase of preferred shares				142,653
Preferred shares price per share				$ 4.94

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Dec. 31, 2017USD ($)Customer	Dec. 31, 2016USD ($)Customer	Dec. 31, 2017USD ($)Customershares	Dec. 29, 2017shares	Dec. 31, 2016USD ($)Customer
Commitments And Contingencies [Line Items]
Rent expense			$ 221,200		$ 108,400
Proceeds from issuance of common stock			$ 10,407,706
Product warranty period			3 years		1 year
Revenue			$ 1,558,866		$ 1,103,277
Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Number of customers | Customer			3		4
Sales Revenue, Net [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Revenue			$ 334,200		$ 253,300
Sales Revenue, Net [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Revenue			241,700		155,800
Sales Revenue, Net [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Revenue			$ 197,800		155,000
Sales Revenue, Net [Member] | Four Customer [Member]
Commitments And Contingencies [Line Items]
Revenue					$ 127,200
Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Number of customers | Customer	3	4
Accounts Receivable [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Revenue	$ 77,640	$ 26,100
Accounts Receivable [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Revenue	52,200	25,700
Accounts Receivable [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Revenue	$ 32,700	24,500
Accounts Receivable [Member] | Four Customer [Member]
Commitments And Contingencies [Line Items]
Revenue		$ 15,200
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			54.00%		64.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			23.00%		23.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			17.00%		14.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			14.00%		14.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Four Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage					12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	55.00%	80.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	26.00%	23.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	18.00%	23.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	11.00%	21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		13.00%
Clinical Research Studies [Member]
Commitments And Contingencies [Line Items]
Contractual amount payable	$ 275,800
Licensing Agreements [Member]
Commitments And Contingencies [Line Items]
Minimum sales covenant			$ 750,000
Licensing Agreements [Member] | Licensors [Member]
Commitments And Contingencies [Line Items]
Stock issued during period | shares			6,172	492
Minimum percentage of outstanding common stock to be maintained			1.00%
Proceeds from issuance of common stock			$ 3,000,000
Licensing Agreements [Member] | Cost of Sales [Member]
Commitments And Contingencies [Line Items]
Royalty charge			$ 25,000		$ 25,000

Commitments and Contingencies75

Commitments and Contingencies - Future Minimum Amounts Due under Agreement (Detail) - Licensing Agreements [Member]	Dec. 31, 2017USD ($)
Finite-Lived Intangible Assets [Line Items]
2,018	$ 25,000
2,019	25,000
2,020	25,000
2,021	25,000
2022 through expiration of the patents	$ 50,000

Commitments and Contingencies76

Commitments and Contingencies - Summary of Changes in Warranty Liability (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Product Warranties Disclosures [Abstract]
Accrual provided for warranties issued during the period Accrued warranty liability, beginning of year	$ 63,147	$ 2,994
Accrual provided for warranties issued during the period	14,867	67,382
Adjustments to prior accruals	570	(3,773)
Actual warranty expenditures	(27,859)	(3,456)
Accrued warranty liability, end of year	$ 50,725	$ 63,147

Income Taxes - Summary of Tax P

Income Taxes - Summary of Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
U.S. federal
Current	$ 0	$ 0
Deferred	(534,000)	(1,184,000)
State and local
Current	0	0
Deferred	(538,000)	(177,000)
Total	(1,072,000)	(1,361,000)
Deferred tax expense related to tax law change	2,909,000
Change in valuation allowance	(1,837,000)	1,361,000
Income tax provision	$ 0	$ 0

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation between U.S. Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. federal statutory rate	34.00%	34.00%
State income taxes, net of federal benefit	4.67%	5.45%
Federal rate change, deferred items	(23.03%)	0.00%
State rate change and other	0.89%	(0.54%)
Non-deductible interest	(17.67%)
Federal NOLs to expire unutilized due to sec 382 limitation	(14.02%)	0.00%
Other permanent items	(0.03%)	(0.29%)
Change in valuation allowance	15.19%	(38.62%)
Effective rate	0.00%	0.00%

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Components of Deferred Tax Assets [Abstract]
Net operating loss carryover	$ 5,925,000	$ 7,876,000
Tax credits	190,000	189,000
Stock-based compensation	53,000	19,000
Other	219,000	140,000
Total deferred tax asset	6,387,000	8,224,000
Less: valuation allowance	(6,387,000)	(8,224,000)
Deferred tax asset, net of valuation allowance	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Net operating loss carryforwards limitations		$ 1,559,000
Operating loss carryforward unutilized		5,000,000
Valuation allowance on net operating loss carryforwards		$ 1,700,000
U.S. federal statutory rate		34.00%	34.00%
Valuation of deferred tax assets due to change in enacted tax rate		$ 3,383,000
Change in valuation allowance		(1,837,000)	$ 1,361,000
Tax penalties and interest		0	0	$ 0
Accrued interest and penalties		0
Tax Liability [Member]
Income Tax [Line Items]
Accrued interest and penalties		0
Scenario, Forecast [Member]
Income Tax [Line Items]
U.S. federal statutory rate	21.00%
Federal [Member]
Income Tax [Line Items]
Net operating loss		$ 26,400,000	20,400,000
Net operating loss beginning year		begin expiring in the year
State [Member]
Income Tax [Line Items]
Net operating loss		$ 22,000,000	$ 16,900,000
Net operating loss beginning year		begin to expire in 2019 through 2027

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Jan. 01, 2018	Aug. 15, 2017	Jun. 09, 2017
Subsequent Event [Line Items]
Warrants, weighted average strike price			$ 6.47
Restricted Stock [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards		46,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued to warrant holders	1,193,556
Number of warrant exercised	1,193,556
Warrants, weighted average strike price	$ 2.95
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards	32,540
Shares of common stock issued upon vesting of stock awards, aggregate fair value	$ 3.85
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards	27,581
Shares of common stock issued upon vesting of stock awards, aggregate fair value	$ 3.65